

CURRICULUM VITAE
Brendan Saloner, PhD

PROFESSIONAL DATA

121 S. Main Street
Room 503
Providence, Rhode Island
401-863-2228 (office)
brendan_saloner@brown.edu
Twitter: @BrendanSaloner

EDUCATION AND TRAINING

Education

PhD/2012	Harvard University Health Policy, Ethics Concentration
BA/2005	University of California, Berkeley Political Economy of Industrial Societies (High Honors); Philosophy

Postdoctoral Training

Postdoc/2012-2014	University of Pennsylvania Robert Wood Johnson Foundation Health and Society Scholar
-------------------	---

PROFESSIONAL EXPERIENCE

Brown University School of Public Health

Donald G. Millar Distinguished Professor of Alcohol and Addiction Studies (*with tenure*), Department of Health Services, Policy, & Practice, July 2025-Present
Associate Director of Policy, Center for Alcohol and Addiction Studies, Brown University School of Public Health, July 2025-Present

Johns Hopkins University

Bloomberg Professor of American Health (*with tenure*), Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, September 2023 – June 2025
Director of the PhD Program, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, July 2023 – June 2025
Director of Practice, Johns Hopkins Center for Mental Health and Addiction Policy Research, August 2023 – June 2025
Bloomberg Associate Professor of American Health, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, July 2020 – September 2023
Associate Professor, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, June 2019 – August 2023

Concentration Director, PhD Program in Bioethics and Health Policy, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, May 2019 – April 2023

Advisory Board, Bloomberg American Health Initiative, Johns Hopkins Bloomberg School of Public Health, 2019 – 2022

Core Faculty, Institute for Health and Social Policy, Johns Hopkins Bloomberg School of Public Health, August 2014 – June 2025

Core Faculty, Johns Hopkins Center for Mental Health and Addiction Policy Research, 2015 – 2025

Core Faculty, Berman Institute of Bioethics, Johns Hopkins University, 2019 – 2025

Affiliated Faculty, Berman Institute of Bioethics, Johns Hopkins University, 2014 – 2019

Affiliated Faculty, Wendy Klag Center for Autism and Developmental Disabilities, 2015 – present

Joint Appointment, Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, 2015 – 2025

Assistant Professor, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, August 2014-May 2019

Other Professional Experience

Summer Associate, The RAND Corporation, Health Group, Arlington, VA, June-August 2009

Summer Associate, The RAND Corporation, Project Air Force, Santa Monica, CA, June-August 2008

Research Assistant, The Urban Institute, Center on Labor, Human Services, and Populations, Washington, DC, February 2006-August 2007

PROFESSIONAL ACTIVITIES

Steering Committee, Opioid Use Disorder Examination and Treatment Act of House Bill 116 of 2019, Maryland Office of Crime Control and Prevention, 2022 – Present

Member, Association of Public Policy and Management, 2009 – 2015

Member, AcademyHealth, 2009 – present

Affiliate, Institute for Research on Poverty, University of Wisconsin, Madison, 2019 – current

Technical Advisor on Data Governance, US Drug Enforcement Administration, 2021-current

Task Force Member on Opioids Report, Association of Schools and Programs of Public Health, 2018 –2019

Bioethics Consultant to the National Academy of Science Engineering and Medicine, Consensus Study on Developing a National Cancer Strategy, 2018 – 2019

Consultant to the Delaware Department of Health and Social Services, 2018 – 2019

Co-leader of Addiction & Overdose Workgroup, Bloomberg American Health Initiative, 2017 2019

Greenwall Anniversary Fellow in Bioethics, National Academy of Medicine, 2016 – 2017

Member, Howard County, MD, Mental Health Task Force, 2014 – 2015

Member, American Society of Health Economics, 2013 – 2014
Senior Fellow, Leonard Davis Institute, University of Pennsylvania, 2012-2014
Graduate Fellow, The Tobin Project, 2010-2012
Graduate Associate, Harvard Institute of Quantitative Social Sciences, 2009-2012

EDITORIAL AND OTHER PEER REVIEW ACTIVITIES

Associate Editor, section on *Noncommunicable Diseases*, the Handbook of Public Health Ethics. Oxford University Press. 2019.

Co-advisor to *Health Affairs* special issue *Research and Policy Insights about the Opioid Crisis* (to be published September 2025)

Journal Peer Review Activities

Addiction; Administration and Policy in Mental Health and Mental Health Services Research; Annals of Internal Medicine; The American Economic Journal – Economic Policy; The American Journal of Bioethics – Empirical; The American Journal of Drug and Alcohol Abuse; The American Journal of Health Economics; The American Journal of Public Health; The American Journal on Addictions; Annals of Internal Medicine; BMC Health Services Research; BMJ; Children and Youth Services; Contemporary Clinical Trials; Drug and Alcohol Dependence; Ethnicity and Health; Governance; Health Affairs; Health Economics; Health Services Research; International Journal of Drug Policy; Israel Journal of Health Policy Research; JAMA; JAMA Health Forum; JAMA Internal Medicine; JAMA Open; JAMA Pediatrics; JAMA Psychiatry; Journal of Adolescent Health; Journal of Health Care for the Poor and Underserved; Journal of Health Economics; Journal of Health Policy, Politics, and Law; Journal of Law and Medical Ethics; Journal of Studies on Alcohol and Drugs; Medical Care; Medical Care Research and Review; Milbank Quarterly; New England Journal of Medicine; Pediatrics; PLOS One; Psychiatric Services; Psychology of Addictive Behaviors; Science; Southern Economics Journal; Substance Abuse Treatment, Prevention, and Policy.

Proposal Reviews

Chair, NIH Special Emphasis Panel (ZRG1 HSS-Z) (April 2026)
Grant Reviewer, NIDA Ad-hoc HEAL (RFA-DA-23-053 & 054) (April 2025)
Grant Reviewer, Bloomberg American Health Initiative (April 2024)
Grant Reviewer, NIDA Ad-hoc Research to Foster an OUD Treatment System Special Panel (June 2023)
Grant Reviewer, Bloomberg American Health Initiative (April 2021, April 2022)
Grant Reviewer, NIDA Ad-hoc Clinical Trials Network (March 2021)
Grant Reviewer, NIDA Special Emphasis Panel (SEP) ZRG1 HDM-Z(02) (March 2021)
Grant Reviewer, National Institute of Health, Mechanism for Time-Sensitive Drug Abuse Research (PAR-19-064) (June 2020)
Grant Reviewer, National Institute of Health, Mechanism for Time-Sensitive Drug Abuse Research (PAR-19-064) (February 2020)
Grant Reviewer, National Institutes of Health, Accelerating the Pace of Drug Abuse Research Using Existing Data (PAR 18-062) (2019)
Co-Chair, Mental Health and Substance Use Section, AcademyHealth Annual Research Meeting (2021)
Grant Reviewer, Health Data for Action (2019)

Abstract Reviewer, Health Section, Association of Public Policy and Management (2019)
Abstract Reviewer, Behavioral Health, AcademyHealth Annual Research Meeting (2017; 2018; 2019)
Grant Reviewer, Robert Wood Johnson Foundation, Policy-Relevant Insurance Studies (2016)
Abstract Reviewer, Coverage and Access, AcademyHealth Annual Research Meeting (2015)
Review of Reports and Other Documents
Report reviewer: National Academies of Science, Engineering and Medicine; RAND Corporation; Pew Charitable Trusts; Vital Strategies

HONORS AND AWARDS

Honors

July 2025 –Appointed as Donald G. Millar Distinguished Professor of Alcohol and Addiction Studies, Brown University School of Public Health
July 2020 –Installed as Bloomberg Associate Professorship of American Health (endowed faculty position as part of the Bloomberg American Health Initiative)

Awards

2023-2026 Scholar, Greenwall Faculty Scholars Program
2025 Excellence in Teaching Citation, Graduate Seminar in Health Policy Term III, Term II
2024 Excellence in Teaching Citation, Graduate Seminar in Health Policy Term II, Term I
2023 Excellence in Teaching Citation, Graduate Seminar in Health Policy Terms II, III
2019 Alice S. Hersh Emerging Leader Award, AcademyHealth (*Since 1986 AcademyHealth has selected one early career recipient. It “recognizes scholars early in their careers as health services researchers who show exceptional promise for future contributions”*)
2019 Excellence in Teaching Citation, Graduate Seminar in Health Policy Terms III, IV
2018 Excellence in Teaching Citation, Graduate Seminar in Health Policy Term III
2017 Article of the Year in Medical Care Research and Review, 2016
2015-2017 Greenwall Fellow in Bioethics at the National Academy of Medicine
2010, 2011 Emerging Scholar, HHS Welfare Evaluation Conference
2011 Joan P. Curhan Citizenship Award, Harvard Program in Health Policy
2010 Buckley Scholar, Manchester Graduate Summer Program in Social Change
2009 Alice S. Hersh Student Scholarship, AcademyHealth

Named Lectureships

April 22, 2025. Eckert Lecture, University of Maryland, Baltimore County.

July 8, 2024. Galkin Lecture, Brown University.

November 7, 2017, Michael M. Davis Lecture, University of Chicago, Center for Health Administration Studies.

PUBLICATIONS

* indicates a mentored student or post-doctoral fellow, + indicates senior authorship

Journal Articles

1. **Saloner B**, Olsen Y. Building a Resilient Substance Use Disorder Treatment Safety Net in An Era of Austerity: Challenges for US State Governments. *Milbank Q*. Published online September 9, 2026. doi:10.1111/1468-0009.70123
2. Green VR, Bandara S, Sugarman OK, Gibbons JB, **Saloner B**, Heidari O. Comparing Buprenorphine Treatment Outcomes Among Kentucky Medicaid Patients by Prescriber Specialty and Type. *Subst Use Misuse*. Published online June 16, 2026:1-8. doi:10.1080/10826084.2026.2687756
3. Miller M, Song M, Bessler A*, **Saloner B** et al. “How are we going to be able to pull that off?”: staff perspectives on the early implementation of mobile medication units in New York State. *Addict Sci Clin Pract*. 2026;21(1). doi:10.1186/s13722-026-00694-y
4. Harris SJ, Desai IK, Situ Y... **Saloner B**+ “I didn’t want to go through the whole rigmarole”: A qualitative exploration of overdose survivor service engagement experiences following nonfatal overdose in seven U.S. states. *J Subst Use Addict Treat*. 2026;191:210093. doi:10.1016/j.josat.2026.210093
5. Sisson LN, Hurst A, Heller D, Bandara S, **Saloner B**, Sugarman OK. “I Really Didn’t Need Treatment, It Was Just a Way for Me Not to Go to Jail”: Court-Mandated Drug Treatment Experiences among Racially Minoritized Individuals in Three US States. *J Urban Health*. 2026;103(3):524-532. doi:10.1007/s11524-025-01048-w
6. Taylor J*, Sisson LN, Bedoya M, **Saloner B** et al. Implementation of a prosecutor-led substance use diversion program in New Jersey. *J Subst Use Addict Treat*. 2026;191:210075. doi:10.1016/j.josat.2026.210075
7. Frank D, Harris SJ, Song M... **Saloner B**, Krawczyk N. “It’s so much easier for them to just come to us”: a qualitative study examining the implementation of mobile methadone treatment serving a residential SUD treatment program. *Addict Sci Clin Pract*. Published online July 1, 2026. doi:10.1186/s13722-026-00692-0
8. **Saloner B**. Mandated Drug Treatment in the Criminal Legal System-a Blunt but Necessary Tool? *Hastings Cent Rep*. 2026;56(3):15-27. doi:10.1002/hast.70038
9. Krawczyk N, Miller M, Frank D.... **Saloner B**+. Mobile but still tied down: Challenges to scaling mobile methadone through a regulatory thicket. *Int J Drug Policy*. 2026;155:105394. doi:10.1016/j.drugpo.2026.105394
10. **Saloner B**. Trends in Public Opinion About US Illicit Drug Policy: Results From the 2000 to 2025 Gallup Survey. *J Addict Med*. Published online June 25, 2026. doi:10.1097/ADM.0000000000001740
11. Jack HE, Wolfer-Jenkins C, Senter Z, Ahsan E, Porter KM, Duenas DM, **Saloner B**, Wurcel A, Berk J. US jail and prison institutional research policies: a lever in access to research for incarcerated people. *Lancet Reg Health Am*. 2026;63:101631. doi:10.1016/j.lana.2026.101631

12. Sugarman OK, Marks C, Whitley P, **Saloner B**, German D. Xylazine-Fentanyl Positivity and Concentration in Urine Drug Tests. *JAMA Netw Open*. 2026;9(7):e2622473. doi:10.1001/jamanetworkopen.2026.22473
13. O'Rourke A, **Saloner B**, Ruelas-Vargas K, et al. Demonstrating the potential for utilizing mobile methadone units to serve medically institutionalized populations in New York State. *J Subst Use Addict Treat*. 2026;188:209981. doi:10.1016/j.josat.2026.209981
14. Sugarman OK, Taylor J*, Harris SJ, Bandara S, **Saloner B**, Krawczyk N. Differences in take-home methadone receipt by state policy and individual social factors in a multistate survey of people who use drugs: A cross-sectional study. *J Subst Use Addict Treat*. 2026;184:209909. doi:10.1016/j.josat.2026.209909
15. **Saloner B**, O'Rourke A, Ruelas-Vargas K, Song M, Ramsey KS, Bandara S. Driving Distance From US Jails to Opioid Treatment Programs. *JAMA Netw Open*. 2026;9(3):e264044. doi:10.1001/jamanetworkopen.2026.4044
16. Taylor J, Jamakandi S*, **Saloner B**⁺. Ethical tensions in legally mandated substance use treatment: A scoping review of participant perspectives. *Addiction*. Published online March 22, 2026. doi:10.1111/add.70394
17. **Saloner B**. Mandated Drug Treatment in the Criminal Legal System-a Blunt but Necessary Tool? *Hastings Cent Rep*. 2026;56(3):15-27. doi:10.1002/hast.70038
18. Desai IK*, Burke K, Raikes J, Xu J*, Li Y, **Saloner B** et al. "They should be like penicillin": barriers to the integration of medications for opioid use disorder in specialty treatment programs. *Addict Sci Clin Pract*. 2025;21(1):3. doi:10.1186/s13722-025-00633-3
19. Gibbons JB, Bandara S, Flanagan V*, Hardy C, Oros M, **Saloner B**⁺. Association between peer support services, treatment engagement and overdose risk among Kentucky Medicaid beneficiaries with opioid use disorder. *Drug Alcohol Depend*. 2025;277:112944. doi:10.1016/j.drugalcdep.2025.112944
20. Gibbons JB, Bandara S, Cook BL... **Saloner B**⁺. Estimating Racial and Ethnic Disparities in Substance Use Disorder Treatment and Harm Reduction Services: Findings From a Survey of People Who Use Drugs. *Health Serv Res*. Published online December 30, 2025:e70081. doi:10.1111/1475-6773.70081
21. Heidari O, **Saloner BK**, Shah H*, et al. Evaluation of a novel coresponse to opioid overdoses with emergency medical services and a community-based organization. *Psychol Serv*. Published online January 19, 2026. doi:10.1037/ser0001017
22. Schuler MS, Sheng F, **Saloner B**, Gordon AJ, Stein BD. High-volume buprenorphine prescribers: Examining state policy contexts. *Drug Alcohol Depend Rep*. 2026;18:100406. doi:10.1016/j.dadr.2025.100406
23. Sugarman OK, Bandara S, Winiker A, **Saloner B**... Heidari O. Self-Advocacy and Perceptions of the Role of Government in the Xylazine Era of the Overdose Crisis: A Qualitative Analysis of Reddit Content. *Subst Use Addict J*. Published online November 5, 2025:29767342251383637. doi:10.1177/29767342251383637
24. Desai IK*, Burke K, Raikes J*, Xu J*, Li Y*, **Saloner B**... Krawczyk N. "They should be like penicillin": barriers to the integration of medications for opioid use disorder in specialty treatment programs. *Addict Sci Clin Pract*. 2025;21(1):3. doi:10.1186/s13722-025-00633-3
25. Shah H, Whaley S, Desai IK, ...**Saloner B**, Harris S. A Qualitative Study on the Impact of COVID-19 on Overdose Risk from the Perspective of Survivors and Witnesses of

- Drug Overdose: Lessons for Future Public Health Emergencies. *Subst Use Misuse*. Published online September 30, 2025:1-9. doi:10.1080/10826084.2025.2562455
26. Maclean JC, Hulser S, Stein BD, **Saloner B**⁺. Medicaid Expansion Boosted Specialty Treatment Episodes For Substance Use Disorder In Expansion States, 2010-22. *Health Aff (Millwood)*. 2025;44(10):1273-1280. doi:10.1377/hlthaff.2024.01289
27. **Saloner B**, Fredericks PJ*, Byrne L, et al. Naloxone Use, 911 Calls, and Emergency Visits After Nonfatal Overdose. *JAMA Netw Open*. 2025;8(10):e2537678. doi:10.1001/jamanetworkopen.2025.37678
28. **Saloner B**, Lagisetty P. The Opioid Crisis: Scaling Up Treatment And Harm Reduction Programs To Reach More People Who Would Benefit. *Health Aff (Millwood)*. 2025;44(9):1034-1041. doi:10.1377/hlthaff.2025.00340
29. Lenz C*, Song M, Bandara S, ... **Saloner B**. Implementation of Jail and Prison-Based Medication Treatment for Opioid Use Disorder Programs: A Narrative Synthesis. *Med Care Res Rev*. Published online June 26, 2025:10775587251345018. doi:10.1177/10775587251345018
30. Taylor J, Bandara S, Thomas CP, **Saloner B**, Fredericks PJ, Shen K. Predictors of non-transport by emergency medical services after a nonfatal opioid overdose: a national analysis. *Health Aff Sch*. 2025;3(5):qxaf101. doi:10.1093/haschl/qxaf101
31. **Saloner B**, Bandara S, Kennedy-Hendricks A. Stable, But Weak: Fifty Years of U.S. Illicit Drug Policy from Nixon to Trump and Beyond. *J Health Polit Policy Law*. Published online June 20, 2025:11995184. doi:10.1215/03616878-11995184
32. Stein BD, Sheng F, **Saloner BK**, Gordon AJ, Merlin JS. Cross-sectional examination of characteristics of higher-dose buprenorphine prescriptions during the era of illicit fentanyl. *Addict Sci Clin Pract*. 2025;20(1):33. doi:10.1186/s13722-025-00547-0
33. Sugarman OK, **Saloner B**, Harris SJ, Irvin R, Flanagan V, Bandara S. Hepatitis C Treatment in Kentucky Medicaid Recipients with Concurrent Opioid Use Disorder: A Cross-Sectional Study. *J Gen Intern Med*. Published online January 21, 2025. doi:10.1007/s11606-025-09356-2
34. Reid MC, Harris SJ, Grieb SM, **Saloner B**, et al. Perspectives of syringe services program operators in Michigan on their relationship with substance use treatment: a qualitative study. *Harm Reduct J*. 2025;22(1):25. doi:10.1186/s12954-025-01172-5
35. Kramer C*, Lenz C*, Song M, ... **Saloner B**⁺. State-Mandated Opioid Use Disorder Treatment In Maryland Jails Helped Patients Recover Despite Gaps In Care. *Health Aff (Millwood)*. 2025;44(5):614-621. doi:10.1377/hlthaff.2024.01423
36. **Saloner B**. The Long Arc of Substance Use Policy Innovation in Medicaid: Looking Back, Looking Forward. *Milbank Q*. Published online March 22, 2025. doi:10.1111/1468-0009.70007
37. **Saloner B**, Heller D, Davis CS, Sherman SG. Harm Reduction: The Neglected Pillar of US Drug Policy. *Annu Rev Public Health*. Published online December 17, 2024. doi:10.1146/annurev-publhealth-071723-112620
38. Bandara S, **Saloner B**, Maniates H*, Song M, Krawczyk N. Implementation of carceral medicaid suspension and enrollment programs: perspectives of carceral and Medicaid leaders. *Health Justice*. 2025;13(1):1. doi:10.1186/s40352-024-00311-7
39. Cook BL, Flores M, Progovac AM, ... **Saloner B**, Ferris Wayne G.. Association of Tobacco Dependence Treatment Coverage Expansion with Smoking Behaviors among

- Medicaid Beneficiaries Living with Substance Use Disorder. *Am J Prev Med*. Published online November 28, 2024:S0749-3797(24)00404-5. doi:10.1016/j.amepre.2024.11.010
40. Stein BD, **Saloner BK**, Sheng F, Sorbero M, Dick AW, Gordon AJ. Associations Between State Policies Facilitating Telehealth and Buprenorphine Episode Initiation and Duration Early in the COVID Pandemic : State Telehealth Policies and Buprenorphine. *J Gen Intern Med*. Published online November 14, 2024. doi:10.1007/s11606-024-09188-6
41. Feder KA, Li Y, Burke KN*,... **Saloner B**, Krawczyk N. Client and program-level factors associated with planned use of medications for opioid use disorder in specialty substance use treatment programs: Evidence from linked administrative data and survey data. *J Subst Use Addict Treat*. 2025;168:209545. doi:10.1016/j.josat.2024.209545
42. **Saloner B**, Sugarman OK, Byrne L, et al. Experiences of the changing illicit drug supply among racial and ethnic minoritized people in three US states: a qualitative study. *Harm Reduct J*. 2024;21(1):205. doi:10.1186/s12954-024-01126-3
43. Sugarman OK, Harris SJ, Byrne L,... **Saloner B**⁺. How emergency departments are responding to the opioid crisis: Results from a statewide survey in Kentucky. *Addict Sci Clin Pract*. 2024;19(1):78. doi:10.1186/s13722-024-00512-3
44. Donahoe JT, Donohue JM, **Saloner B**⁺. Disparities in Medication Use for Criminal Justice System-Referred Opioid Use Disorder Treatment. *JAMA Health Forum*. 2024;5(9):e242807. doi:10.1001/jamahealthforum.2024.2807
45. Harris SJ, Golberstein E, Maclean JC, Stein BD, Ettner SL, **Saloner B**⁺. Implementation Of New Mexico's "No Behavioral Health Cost Sharing" Law: A Qualitative Study. *Health Aff (Millwood)*. 2024;43(10):1448-1454. doi:10.1377/hlthaff.2024.00101
46. Heidari O, Sugarman OK, Winiker AK*,... **Saloner B**⁺. Personal Experiences With Xylazine and Behavior Change: A Qualitative Content Analysis of Reddit Posts. *J Addict Med*. Published online September 27, 2024. doi:10.1097/ADM.0000000000001383
47. Gibbons JB, Sugarman OK, Byrne L,...**Saloner B**⁺. Perceptions of a naloxone leave behind program among emergency medical services personnel in Michigan, USA. *Drug Alcohol Depend Rep*. 2024;12:100273. doi:10.1016/j.dadr.2024.100273
48. Bandara S, Byrne L, Berman V... **Saloner B**⁺. Harm Reduction and Treatment Among People at High Risk of Overdose. *JAMA Netw Open*. 2024;7(8):e2427241. doi:10.1001/jamanetworkopen.2024.27241
49. Li W, Eisenberg M, Song M, Kennedy-Hendricks A, **Saloner B**⁺. Medications for Opioid Use Disorder after Entering Residential Treatment: Evidence from Louisiana Medicaid. *J Addict Med*. Published online August 16, 2024. doi:10.1097/ADM.0000000000001373
50. Sugarman OK, Shah H, Whaley S, McCourt A, **Saloner B**, Bandara S. A content analysis of legal policy responses to xylazine in the illicit drug supply in the United States. *Int J Drug Policy*. 2024;129:104472. doi:10.1016/j.drugpo.2024.104472
51. Blumenthal-Barby J, Fletcher FE, Taylor L, **Saloner B** et al. Ethical Complexities in Utilizing Artificial Intelligence for Surrogate Decision Making. *Am J Bioeth*. 2024;24(7):1-2. doi:10.1080/15265161.2024.2362553
52. Harris SJ, Golberstein E, Maclean JC, Stein BD, Ettner SL, **Saloner B**⁺. How policymakers innovate around behavioral health: adoption of the New Mexico "No Behavioral Health Cost-Sharing" law. *Health Aff Sch*. 2024;2(1):qxad081. doi:10.1093/haschl/qxad081

53. Drake C, Nagy D, Meiselbach MK, Zhu J, **Saloner B**, et al. Racial and Ethnic Disparities in Geographic Availability of Buprenorphine. *J Addict Med*. 2024;18(3):335-338. doi:10.1097/ADM.0000000000001287
54. McGinty EE, White SA, Eisenberg MD, Palmer NR, Brown CH, **Saloner BK⁺**. US payment policy for medications to treat opioid use disorder: landscape and opportunities. *Health Aff Sch*. 2024;2(3):qxae024. doi:10.1093/haschl/qxae024
55. Doan B, Kramer C*, **Saloner B**, et al. Allocating health care resources in jails and prisons during COVID-19: a qualitative study of carceral decision-makers. *Health Aff Sch*. 2024;2(4):qxae015. doi:10.1093/haschl/qxae015
56. Kennedy-Hendricks A, Song M, McCourt AD, Sharfstein JM, Eisenberg MD, **Saloner B⁺**. Licensure Policies May Help States Ensure Access To Opioid Use Disorder Medication In Specialty Addiction Treatment. *Health Aff (Millwood)*. 2024;43(5):732-739. doi:10.1377/hlthaff.2023.01306
57. Gibbons JB, Harris SJ, Sugarman OK... **Saloner B⁺**. Piloting racial bias training for hospital emergency department providers treating patients with opioid use disorder. *Health Aff Sch*. 2024;2(5):qxae049. doi:10.1093/haschl/qxae049
58. Drake C, Nagy D, Meiselbach MK, **Saloner B**, et al. Racial and Ethnic Disparities in Geographic Availability of Buprenorphine. *J Addict Med*. 2024;18(3):335-338. doi:10.1097/ADM.0000000000001287
59. **Saloner B**. The Overdose Crisis in the 2024 Election-Political Fights and Practical Problems. *JAMA*. 2024;331(19):1621-1622. doi:10.1001/jama.2024.4997
60. Harris SJ, Landis RK, Li W, Stein BD, **Saloner B⁺**. Utilization of Medications for Opioid Use Disorder Among West Virginia Medicaid Enrollees Following Medicaid Coverage of Methadone. *Subst Use Addctn J*. 2024;45(1):91-100. doi:10.1177/29767342231208516
61. Lyle V, Harris S, Heidari O, ... **Saloner B**, Gibbons J. Association between high-threshold practices and buprenorphine treatment termination. *International Journal of Drug Policy*. 2024;124:104318.
62. Sugarman OK, **Saloner B**, Richards TM, et al. Association of buprenorphine retention and subsequent adverse outcomes following non-fatal overdose: An analysis using statewide linked Maryland databases. *Drug and alcohol dependence*. Published online 2024:111281.
63. Schuler MS, Dick AW, Gordon AJ, **Saloner B**, Kerber R, Stein BD. Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009-2018. *Drug and Alcohol Dependence*. Published online 2024:111290.
64. Golberstein E, Campbell JM, Maclean JC, Harris SJ, **Saloner B**, Stein BD. Prescription Drug Dispensing and Patient Costs After Implementation of a No Behavioral Health Cost-Sharing Law. *JAMA Health Forum*; 2024:e240198-e240198.
65. Schneider KE, Martin EM, Allen ST, ... **Saloner B**, Sherman SG. Volatile drug use and overdose during the first year of the COVID-19 pandemic in the United States. *International Journal of Drug Policy*. 2024;126:104371.
66. Harris SJ, Golberstein E, Maclean JC, Stein BD, Ettner SL, **Saloner B⁺**. How policymakers innovate around behavioral health: adoption of the New Mexico “No Behavioral Health Cost-Sharing” law. *Health Affairs Scholar*. 2024;2(1):qxad081.

67. Sugarman OK, Li W, **Saloner B**. Medications For Opioid Use Disorder Increased Among Louisiana Medicaid Enrollees During Policy Reforms, 2018-21. *Health Aff (Millwood)*. 2024;43(1):46-54. doi:10.1377/hlthaff.2023.00715
68. Gibbons JB, Li W, Stuart EA, **Saloner B**⁺. Simulated impact of mobile opioid treatment program units on increasing access to methadone for opioid use disorder. *Health Serv Res*. Published online January 8, 2024. doi:10.1111/1475-6773.14271
69. Green VR*, Kennedy-Hendricks A, **Saloner B**, Bandara S. Substance use and treatment characteristics among pregnant and non-pregnant females, 2015-2019. *Drug Alcohol Depend*. 2023;254:111041. doi:10.1016/j.drugalcdep.2023.111041
70. Landis RK, Stein BD, Dick AW, **Saloner B** et al. Trends and Disparities in Perinatal Opioid Use Disorder Treatment in Medicaid, 2007-2012. *Med Care Res Rev*. Published online December 31, 2023:10775587231216515. doi:10.1177/10775587231216515
71. Song M, Desai IK, Meyer A*, Shah H*, **Saloner B**, Sherman SG, Allen ST, Tomko C, Schneider KE, Krawczyk N, Whaley S, Churchill J, Harris SJ. Exploring trauma and wellbeing of people who use drugs after witnessing overdose: A qualitative study. *Int J Drug Policy*. 2023 Oct 25;122:104239. doi: 10.1016/j.drugpo.2023.104239.
72. **Saloner B**. A Chance to Modernize Health Care behind Bars - Section 1115 Medicaid Inmate Exclusion Waivers. *N Engl J Med*. 2023 Oct 19;389(16):1449-1451. doi: 10.1056/NEJMp2307641. Epub 2023 Oct 14.
73. Heidari O, Shah H*, Bhagwat A*, Ahmad NJ, Whaley S, Sherman SG, Morris M, **Saloner B**. Changes in opioid treatment programs and harm reduction provider services during the COVID-19 pandemic: Findings from 10 states. *Psychol Serv*. 2023 Oct 12. doi: 10.1037/ser0000805.
74. Feder KA, Byrne L, Miller SM, Sodder S, **Saloner B**⁺. Beliefs and Attitudes about Vermont's Buprenorphine Decriminalization Law among Clinicians Who Prescribe Buprenorphine. *Subst Use Misuse*. Published online September 26, 2023:1-4. doi:10.1080/10826084.2023.2262014
75. Tilhou AS, **Saloner B**, DeLeire T, Chakraborty S, Dague L. Health and health care access for essential, non-essential and non-workers during the COVID-19 pandemic. *J Occup Environ Med*. Published online August 28, 2023. doi:10.1097/JOM.0000000000002953
76. Kramer C, Song M, Sufrin CB, Eber GB, Rubenstein LS, **Saloner B**⁺. Release, Reentry, and Reintegration During COVID-19: Perspectives of Individuals Recently Released from the Federal Bureau of Prisons. *Health Equity*. 2023;7(1):384-394. doi:10.1089/heq.2022.0172
77. Andraka-Christou B, McAvoy E, Gordon AJ, **Saloner B**, et al. Urine drug testing when prescribing opioid analgesics for chronic pain: A content analysis of U.S. state laws in 2022. *Pain Med*. Published online August 8, 2023:pnad103. doi:10.1093/pm/pnad103
78. **Saloner B**, Andraka-Christou B, Stein BD, Gordon AJ. Will the End of the X-Waiver Expand Access to Buprenorphine Treatment? Achieving the Full Potential of the 2023 Consolidated Appropriations Act. *Subst Abus*. Published online September 7, 2023:8897077231186212. doi:10.1177/08897077231186212
79. Feder KA, Harris SJ*, Byrne L... **Saloner B**⁺. Attitudes and beliefs about Vermont's 2021 buprenorphine decriminalization law among residents who use illicit opioids. *Drug Alcohol Depend*. 2023;250:110879. doi:10.1016/j.drugalcdep.2023.110879

80. **Saloner B**, Kramer C, Song M, et al. COVID-19 Restrictions In Jails And Prisons: Perspectives From Carceral Leaders. *Health Aff (Millwood)*. 2023;42(6):841-848. doi:10.1377/hlthaff.2022.01473
81. Landis RK, Stein BD, Griffin BA, **Saloner BK**, Terplan M, Faherty LJ. Disparities in Perinatal and Emergency Care Receipt Among Women With Perinatal Opioid Use Disorder in Medicaid, 2007 to 2012. *J Addict Med*. Published online June 30, 2023. doi:10.1097/ADM.0000000000001199
82. Griffin BA, Cabrerros I, **Saloner B**, Gordon AJ, Kerber R, Stein BD. Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads. *Subst Abus*. Published online July 4, 2023:8897077231179824. doi:10.1177/08897077231179824
83. Schuler MS, **Saloner B**, Gordon AJ, Dick AW, Stein BD. National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018. *Subst Abus*. Published online June 6, 2023:8897077231179576. doi:10.1177/08897077231179576
84. Kramer C, Song M, Sufrin CB, Eber GB, Rubenstein LS, **Saloner B⁺**. Release, Reentry, and Reintegration During COVID-19: Perspectives of Individuals Recently Released from the Federal Bureau of Prisons. *Health Equity*. 2023;7(1):384-394. doi:10.1089/heq.2022.0172
85. Gibbons JB*, Harris SJ*, Solomon KT, Sugarman O, Hardy C, **Saloner B⁺**. Increasing overdose deaths among Black Americans: a review of the literature. *Lancet Psychiatry*. Published online May 23, 2023:S2215-0366(23)00119-0. doi:[10.1016/S2215-0366\(23\)00119-0](https://doi.org/10.1016/S2215-0366(23)00119-0)
86. **Saloner B**, Whitley P, Dawson E, Passik S, Gordon AJ, Stein BD. Polydrug use among patients on methadone medication treatment: Evidence from urine drug testing to inform patient safety. *Addiction*. Published online May 9, 2023. doi:[10.1111/add.16180](https://doi.org/10.1111/add.16180)
87. Meiselbach MK, Drake C, Zhu JM,...**Saloner B** et al. State Policy and the Breadth of Buprenorphine-Prescriber Networks in Medicaid Managed Care. *Med Care Res Rev*. Published online April 21, 2023:10775587231167514. doi:[10.1177/10775587231167514](https://doi.org/10.1177/10775587231167514)
88. Song M, Kramer CT, Sufrin CB, et al...**Saloner B⁺**. “It was like you were being literally punished for getting sick”: formerly incarcerated people’s perspectives on liberty restrictions during COVID-19. *AJOB Empir Bioeth*. Published online February 22, 2023:1-12. doi:[10.1080/23294515.2023.2180105](https://doi.org/10.1080/23294515.2023.2180105)
89. Allen ST, Schneider KE, Morris M, et al...**Saloner B**, Sherman SG. Factors associated with receptive injection equipment sharing among people who inject drugs: findings from a multistate study at the start of the COVID-19 pandemic. *Harm Reduct J*. 2023;20(1):18. doi:[10.1186/s12954-023-00746-5](https://doi.org/10.1186/s12954-023-00746-5)
90. Treitler P, Nowels M, Feder KA, **Saloner B** et al. Hospital Use and Mortality Among Decarcerated Individuals With Substance Use Disorder After a Large-scale COVID-19 Emergency Prison Release Program. *JAMA Health Forum*. 2023;4(6):e231200. doi:[10.1001/jamahealthforum.2023.1200](https://doi.org/10.1001/jamahealthforum.2023.1200)
91. Curran J, **Saloner B**, Winkelman TNA, Alexander GC. Estimated Use of Prescription Medications Among Individuals Incarcerated in Jails and State Prisons in the US. *JAMA Health Forum*. 2023;4(4):e230482. doi:[10.1001/jamahealthforum.2023.0482](https://doi.org/10.1001/jamahealthforum.2023.0482)
92. Stein BD, **Saloner BK**, Golan OK, et al. Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment. *JAMA Health Forum*. 2023;4(5):e231102. doi:[10.1001/jamahealthforum.2023.1102](https://doi.org/10.1001/jamahealthforum.2023.1102)

93. Andraka-Christou B, Golan O, Totaram R, **Saloner B** et al. Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019. *Ann Med*. 2023;55(1):514-520. doi:10.1080/07853890.2023.2171107
94. Pytell JD*, Whitley P, Passik SD, Bundy WL, Dawson E, **Saloner B**+. Association of Patients' Direct Addition of Buprenorphine to Urine Drug Test Specimens With Clinical Factors in Opioid Use Disorder. *JAMA Psychiatry*. 2023;80(5):459-467. doi:10.1001/jamapsychiatry.2023.0234
95. Solomon KT*, O'Connor J, Gibbons JB*, **Saloner B** et al. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge. *JAMA Health Forum*. 2023;4(3):e230245. doi:10.1001/jamahealthforum.2023.0245
96. Bono MH*, Treitler P*, **Saloner B**, Crystal S. Returning home during the pandemic: a thematic analysis describing experiences of people with substance use disorders released early from New Jersey prisons during COVID-19. *Health Justice*. 2023;11(1):11. doi:10.1186/s40352-023-00208-x
97. Kramer C, Song M, Sufrin CB, Eber GB, Rubenstein LS, **Saloner B**+. COVID-19 vaccination hesitancy and uptake: Perspectives from people released from the Federal Bureau of Prisons. *Vaccine*. 2023;41(7):1408-1417. doi:10.1016/j.vaccine.2023.01.039
98. **Saloner B**, Chang HY, Alexander GC, Stein BD. Discontinuation of Buprenorphine Treatment for Opioid Use Disorder During the Coronavirus Disease-2019 Pandemic: A Multilevel Framework. *Med Care*. 2023;61(2):95-101. doi:10.1097/MLR.0000000000001802
99. **Saloner B**, Li W, Flores M, Progovac AM, Lê Cook B. A Widening Divide: Cigarette Smoking Trends Among People With Substance Use Disorder And Criminal Legal Involvement. *Health Aff (Millwood)*. 2023;42(2):187-196. doi:10.1377/hlthaff.2022.00901
100. Allen L, Burns M, **Saloner B**. The Consequences of Removing Prior Authorization for Buprenorphine in Medicaid-Building an Evidence Base. *JAMA Health Forum*. 2022;3(6):e220189. doi:10.1001/jamahealthforum.2022.0189
101. Stein BD, Landis RK, Sheng F, **Saloner B** et al. Buprenorphine Treatment Episodes During the First Year of COVID: a Retrospective Examination of Treatment Initiation and Retention. *J Gen Intern Med*. 2023;38(3):733-737. doi:10.1007/s11606-022-07891-w
102. Landis RK, Oppen I, **Saloner B**, et al. Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies. *Drug Alcohol Depend*. 2022;241:109669. doi:10.1016/j.drugalcdep.2022.109669
103. Allen ST, Schneider KE, Morris M, **Saloner B**, Sherman SG. Factors Associated with HIV Testing Among People Who Inject Drugs: Findings from a Multistate Study at the Start of the COVID-19 Pandemic. *AIDS Behav*. 2023;27(5):1674-1681. doi:10.1007/s10461-022-03899-9
104. Alinsky RH, Prichett L, Chang HY, Alexander GC, Stein BD, **Saloner B**+. Treatment of Opioid Use Disorder With Buprenorphine Among US Adolescents and Young Adults During the Early COVID-19 Pandemic. *J Adolesc Health*. 2022;71(2):239-241. doi:10.1016/j.jadohealth.2022.03.015

105. Schneider KE, Allen ST, Rouhani S, **Saloner B** et al. Increased solitary drug use during COVID-19: An unintended consequence of social distancing. *Int J Drug Policy*. 2022;111:103923. doi:10.1016/j.drugpo.2022.103923
106. Krawczyk N, Allen ST, Schneider KE... **Saloner B**⁺. Intersecting substance use treatment and harm reduction services: exploring the characteristics and service needs of a community-based sample of people who use drugs. *Harm Reduct J*. 2022;19(1):95. doi:10.1186/s12954-022-00676-8
107. **Saloner B**, Campbell J*, Gollust S, Blewett LA. Changes in Material Hardship During the First Year of the COVID-19 Pandemic. *JAMA Health Forum*. 2022;3(2):e215213. doi:10.1001/jamahealthforum.2021.5213
108. Carroll G, Solomon K*, Heil J, **Saloner B**, Stuart EA, Patel EY, Greifer N, Salzman M, Murphy E, Baston K, Haroz R. Impact of Administering Buprenorphine to Overdose Survivors Using Emergency Medical Services. *Annals of Emergency Medicine*. 2023;81(2):165-175. doi: 10.1016/j.annemergmed.2022.07.006.
109. Levin JS, Landis RK, Sorbero M, Dick AW, **Saloner B**, Stein BD. Differences in buprenorphine treatment quality across physician provider specialties. *Drug Alcohol Depend*. 2022;237:109510. doi:10.1016/j.drugalcdep.2022.109510
110. Andraka-Christou B, **Saloner B**, Gordon AJ, et al. Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C. *Am J Drug Alcohol Abuse*. 2022;48(4):492-503. doi:10.1080/00952990.2022.2082301
111. Patel SY, Wayne GF, Progovac AM, **Saloner B**, Cook BL. Effects of Medicaid coverage on receipt of tobacco dependence treatment among Medicaid beneficiaries with substance use disorder. *Health Serv Res*. 2022;57(6):1303-1311. doi:10.1111/1475-6773.14007
112. Stein BD, **Saloner B**, Kerber R, Sorbero M, Gordon AJ. Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020. *Ann Emerg Med*. 2022;79(5):441-450. doi:10.1016/j.annemergmed.2022.01.042
113. Meiselbach MK*, Drake C, **Saloner B**, Zhu JM, Stein BD, Polsky D. Medicaid Managed Care: Access To Primary Care Providers Who Prescribe Buprenorphine. *Health Aff (Millwood)*. 2022;41(6):901-910. doi:10.1377/hlthaff.2021.01719
114. **Saloner B**, Eber GB, Sufrin CB, Beyrer C, Rubenstein LS. A Human Rights Framework for Advancing the Standard of Medical Care for Incarcerated People in the United States in the Time of COVID-19. *Health Hum Rights*. 2022;24(1):59-75.
115. Krawczyk N, Bandara S, Merritt S*... **Saloner B**⁺. Jail-based treatment for opioid use disorder in the era of bail reform: a qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative. *Addict Sci Clin Pract*. 2022;17(1):30. doi:10.1186/s13722-022-00313-6
116. Ferris LM*, Weiner JP, **Saloner B**, Kharrazi H. Comparing person-level matching algorithms to identify risk across disparate datasets among patients with a controlled substance prescription: retrospective analysis. *JAMIA Open*. 2022;5(1):ooac020. doi:10.1093/jamiaopen/ooac020.
117. Tilhou AS, Dague L, **Saloner B**, Beemon D, Burns M. Trends in Engagement With Opioid Use Disorder Treatment Among Medicaid Beneficiaries During the COVID-19 Pandemic. *JAMA Health Forum*. 2022;3(3):e220093. doi:10.1001/jamahealthforum.2022.0093.

118. **Saloner B**, Li W, Bandara SN, McGinty EE, Barry CL. Trends In The Use Of Treatment For Substance Use Disorders, 2010-19. *Health Affairs*. 2022;41(5):696-702. doi: 10.1377/hlthaff.2021.01767.
119. Landis RK*, Levin JS, **Saloner B**, Gordon, AJ, Dick AW, Sherry, TB, ... & Stein BD Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine. *Substance Abuse*. 2022;43(1), 1057-1071.
120. Andraka-Christou B, Randall-Kosich O, Golan M, **Saloner B**, et al. A national survey of state laws regarding medications for opioid use disorder in problem-solving courts. *Health Justice*. 2022;10(1):14. doi:10.1186/s40352-022-00178-6
121. Bandara S, Maniates H*, Hulsey E, **Saloner B**, et al. Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey. *BMC Health Serv Res*. 2022;22(1):418. doi:10.1186/s12913-022-07832-7
122. Krawczyk N, Maniates H*, Hulsey E, DiDomenico E, Stuart EA, **Saloner B**, et al. Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs. *J Addict Med*. 2022;16(6):645-652. doi:10.1097/ADM.0000000000000981
123. **Saloner B**, Landis RK*, Jayakrishnan R*, Stein BD, Barry CL. A bridge too far? Distance to waived physicians and utilization of buprenorphine treatment for opioid use disorder in West Virginia Medicaid. *Subst Abus*. 2022;43(1):682-690. doi:10.1080/08897077.2021.1986882
124. Gibbons JB*, Stuart EA, **Saloner B**⁺. Methadone on Wheels-A New Option to Expand Access to Care Through Mobile Units. *JAMA Psychiatry*. 2022;79(3):187-188. doi:10.1001/jamapsychiatry.2021.3716
125. Barry CL, **Saloner B**. Using Policy Tools to Improve Population Health - Combating the U.S. Opioid Crisis. *N Engl J Med*. 2021;385(23):2113-2116. doi:10.1056/NEJMp2102323
126. Thakrar AP, Alexander GC, **Saloner B**⁺. Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021. *JAMA Netw Open*. 2021;4(12):e2138807. doi:10.1001/jamanetworkopen.2021.38807
127. **Saloner B**, Krawczyk N, Solomon K*, et al. Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey. *Int J Drug Policy*. 2021;101:103537. doi:10.1016/j.drugpo.2021.103537
128. Marquez N*, Ward JA, Parish K, **Saloner B**, Dolovich S. COVID-19 Incidence and Mortality in Federal and State Prisons Compared With the US Population, April 5, 2020, to April 3, 2021. *JAMA*. 2021;326(18):1865-1867. doi:10.1001/jama.2021.17575
129. Patel E*, Solomon K*, Saleem H, **Saloner B**, et al. Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals. *J Subst Abuse Treat*. 2022;136:108658. doi:10.1016/j.jsat.2021.108658
130. Lee D*, **Saloner B**, Barnett M. Advanced Practice Providers and Buprenorphine Access in the United States After the Comprehensive Addiction and Recovery Act. *Psychiatr Serv*. 2021;72(11):1358-1359. doi:10.1176/appi.ps.202100122
131. Cabrerros I, Griffin BA, **Saloner B**, Gordon AJ, Kerber R, Stein BD. Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories. *Drug Alcohol Depend*. 2021;228:109089. doi:10.1016/j.drugalcdep.2021.109089

132. **Saloner B**, Whitley P, LaRue L, Dawson E, Huskey A. Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database. *JAMA Netw Open*. 2021;4(9):e2123019. doi:10.1001/jamanetworkopen.2021.23019
133. Kennedy-Hendricks A, Bandara S, Merritt S*, Barry CL, **Saloner B**⁺. Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision. *Drug Alcohol Depend*. 2021;226:108881. doi:10.1016/j.drugalcdep.2021.108881
134. Solomon KT*, Bandara S, Reynolds IS, **Saloner, B** et al. Association between availability of medications for opioid use disorder in specialty treatment and use of medications among patients: A state-level trends analysis. *Journal of Substance Abuse Treatment*. 2022;132:108424. doi:10.1016/j.jsat.2021.108424
135. Krawczyk N, Williams AR, **Saloner B**, Cerdá M. Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings. *Journal of Substance Abuse Treatment*. 2021;126:108329. doi:10.1016/j.jsat.2021.108329
136. Fabi RE*, **Saloner B**, Taylor H. State Policymaking and Stated Reasons: Prenatal Care for Undocumented Immigrants in an Era of Abortion Restriction. *The Milbank Quarterly*. 2021;99(3):693-720. doi:10.1111/1468-0009.12519
137. Stein BD, **Saloner B**, Schuler MS, Gurvey J, Sorbero M, Gordon AJ. Concentration of Patient Care Among Buprenorphine-Prescribing Clinicians in the US. *JAMA*. 2021;325(21):2206. doi:10.1001/jama.2021.4469
138. Patel E, Bandara S, **Saloner B**, et al. Heterogeneity in prenatal substance use screening despite universal screening recommendations: findings from PRAMS, 2016-2018. *American Journal of Obstetrics & Gynecology MFM*. 2021;3(5):100419. doi:10.1016/j.ajogmf.2021.100419
139. Ward JA*, Parish K, DiLaura G, Dolovich S, **Saloner B**⁺. COVID-19 Cases Among Employees of U.S. Federal and State Prisons. *Am J Prev Med*. 2021;60(6):840-844. doi:10.1016/j.amepre.2021.01.018
140. Bandara S, Kennedy-Hendricks A, Merritt S*, Barry CL, **Saloner B**⁺. Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters. *Addiction*. 2021;116(12):3472-3481. doi:10.1111/add.15565
141. Anderson KE*, **Saloner B**, Eckstein J, et al. Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder. *Med Care*. 2021;59(5):393-401. doi:10.1097/MLR.0000000000001530
142. Nguyen TD, **Saloner B**, Stein BD. Buprenorphine Opioid Treatment During the COVID-19 Pandemic-Reply. *JAMA Intern Med*. 2021;181(8):1135-1136. doi:10.1001/jamainternmed.2021.0774
143. Pollack CE, **Saloner B**, Lucas S, Warren E, Chaubal M, Kennedy-Hendricks A. Leveraging the Affordable Housing Sector to Respond to the Opioid Crisis. *Public Health Rep*. 2022;137(3):414-419. doi:10.1177/00333549211007591
144. Nguyen TD, Gupta S, Ziedan E, **Saloner B**, et al. Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic. *JAMA Intern Med*. 2021;181(4):562-565. doi:10.1001/jamainternmed.2020.7497
145. Kane EI*, Daumit GL, Fain KM, **Saloner B**, Scherer RW, McGinty EE. National Institute of Mental Health Recruitment Monitoring Policy and Clinical Trial Impact.

- Contemporary Clinical Trials*. 2021;103:106312.
<https://doi.org/10.1016/j.cct.2021.106312>.
146. Krawczyk N, Garrett B,* Ahmad NJ,* Patel E,* Solomon K,* Stuart EA, **Saloner B.** + Medications for Opioid Use Disorder among American Indians and Alaska Natives: Availability and Use across a National Sample. *Drug and Alcohol Dependence*. 2021;220:108512. <https://doi.org/10.1016/j.drugalcdep.2021.108512>.
 147. Maclean JC, Wen H, Simon KI, **Saloner B.** Institutions For Mental Diseases Medicaid Waivers: Impact On Payments For Substance Use Treatment Facilities. *Health Affairs (Project Hope)*. 2021;40(2):326–33. <https://doi.org/10.1377/hlthaff.2020.00404>.
 148. Ferris LM*, **Saloner B**, Jackson K, et al. Performance of a Predictive Model versus Prescription-Based Thresholds in Identifying Patients at Risk of Fatal Opioid Overdose. *Subst Use Misuse*. 2021;56(3):396-403. doi:10.1080/10826084.2020.1868520
 149. Nguyen TD, Gupta S, Ziedan E, Simon K, Alexander C, **Saloner B**, Stein B. Assessment of Filled Buprenorphine Prescriptions for Opioid Use Disorder During the Coronavirus Disease 2019 Pandemic. *JAMA Intern Med*. 2021;181(4):562-565. doi:10.1001/jamainternmed.2020.7497
 150. Wen H, Barnett ML, **Saloner B**+. Clinical Risk Factors for COVID-19 Among People With Substance Use Disorders. *Psychiatr Serv*. 2020;71(12):1308. doi:10.1176/appi.ps.202000215
 151. Cantor J, Stein BD, **Saloner B**+. Telehealth Capability Among Substance Use Disorder Treatment Facilities in Counties With High Versus Low COVID-19 Social Distancing. *J Addict Med*. 2020;14(6):e366-e368. doi:10.1097/ADM.0000000000000744
 152. Gollust SE, **Saloner B**, Hest R, Blewett LA. US Adults' Preferences for Public Allocation of a Vaccine for Coronavirus Disease 2019. *JAMA Netw Open*. 2020;3(9):e2023020. doi:10.1001/jamanetworkopen.2020.23020
 153. **Saloner B**, Gollust SE, Planalp C, Blewett LA. Access and enrollment in safety net programs in the wake of COVID-19: A national cross-sectional survey. *PLoS One*. 2020;15(10):e0240080. doi:10.1371/journal.pone.0240080
 154. Chang H-Y, Ferris L*, Eisenberg M... **Saloner B** The Impact of Various Risk Assessment Time Frames on the Performance of Opioid Overdose Forecasting Models. *Med Care*. 2020;58(11):1013-1021. doi:10.1097/MLR.0000000000001389
 155. Bandara S, Kennedy-Hendricks A, Merritt S*, Barry CL, **Saloner B**+. Early Effects of COVID-19 on Programs Providing Medications for Opioid Use Disorder in Jails and Prisons. *J Addict Med*. 2020;14(5):e257-e260. doi:10.1097/ADM.0000000000000718
 156. Alinsky RH*, Hadland SE, Matson PA, Cerda M, **Saloner B**+. Adolescent-Serving Addiction Treatment Facilities in the United States and the Availability of Medications for Opioid Use Disorder. *J Adolesc Health*. 2020;67(4):542-549. doi:10.1016/j.jadohealth.2020.03.005
 157. Park JN, Rouhani S*, Beletsky L, Vincent L, **Saloner B**, Sherman SG. Situating the Continuum of Overdose Risk in the Social Determinants of Health: A New Conceptual Framework. *Milbank Q*. 2020;98(3):700-746. doi:10.1111/1468-0009.12470
 158. McClellan C, Maclean JC, **Saloner B**, McGinty EE, Pesko MF. Integrated care models and behavioral health care utilization: Quasi- experimental evidence from Medicaid health homes. *Health Econ*. 2020;29(9):1086-1097. doi:10.1002/heal.4027

159. Krawczyk N*, Mojtabai R, Stuart EA... **Saloner B**⁺. Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. *Addiction*. 2020;115(9):1683-1694. doi:10.1111/add.14991
160. Beetham T, **Saloner B**, Gaye M, Wakeman SE, Frank RG, Barnett ML. Therapies Offered at Residential Addiction Treatment Programs in the United States. *JAMA*. 2020;324(8):804-806. doi:10.1001/jama.2020.8969
161. **Saloner B**, Parish K, Ward JA*, DiLaura G, Dolovich S. COVID-19 Cases and Deaths in Federal and State Prisons. *JAMA*. 2020;324(6):602-603. doi:10.1001/jama.2020.12528
162. **Saloner B**, Lin L, Simon K. Geographic location of buprenorphine-waivered physicians and integration with health systems. *J Subst Abuse Treat*. 2020;115:108034. doi:10.1016/j.jsat.2020.108034
163. Burns ME, Dague L, **Saloner B**, et al. Implementing parity for mental health and substance use treatment in Medicaid. *Health Serv Res*. 2020;55(4):604-614. doi:10.1111/1475-6773.13309
164. Alexander GC, Stoller KB, Haffajee RL, **Saloner B**⁺. An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19. *Ann Intern Med*. 2020;173(1):57-58. doi:10.7326/M20-1141
165. **Saloner B**, Chang H-Y, Krawczyk N*, et al. Predictive Modeling of Opioid Overdose Using Linked Statewide Medical and Criminal Justice Data. *JAMA Psychiatry*. 2020;77(11):1155-1162. doi:10.1001/jamapsychiatry.2020.1689
166. Krawczyk N*, Schneider KE*, Eisenberg MD ... **Saloner B**⁺. Opioid overdose death following criminal justice involvement: Linking statewide corrections and hospital databases to detect individuals at highest risk. *Drug Alcohol Depend*. 2020;213:107997. doi:10.1016/j.drugalcdep.2020.107997
167. Wen H, Soni A, Hollingsworth A ... **Saloner B**⁺. Association Between Medicaid Expansion and Rates of Opioid-Related Hospital Use. *JAMA Intern Med*. 2020;180(5):753-759. doi:10.1001/jamainternmed.2020.0473
168. Wen H, Druss BG, **Saloner B**. Self-Help Groups And Medication Use In Opioid Addiction Treatment: A National Analysis. *Health Aff (Millwood)*. 2020;39(5):740-746. doi:10.1377/hlthaff.2019.01021
169. **Saloner B**, Maclean JC. Specialty Substance Use Disorder Treatment Admissions Steadily Increased In The Four Years After Medicaid Expansion. *Health Aff (Millwood)*. 2020;39(3):453-461. doi:10.1377/hlthaff.2019.01428
170. Samples H*, Stuart EA, **Saloner B**, Barry CL, Mojtabai R. The Role of Screening in Depression Diagnosis and Treatment in a Representative Sample of US Primary Care Visits. *J Gen Intern Med*. 2020;35(1):12-20. doi:10.1007/s11606-019-05192-3
171. Krawczyk N*, Eisenberg M, Schneider KE ... **Saloner B**⁺. Predictors of Overdose Death Among High-Risk Emergency Department Patients With Substance-Related Encounters: A Data Linkage Cohort Study. *Ann Emerg Med*. 2020;75(1):1-12. doi:10.1016/j.annemergmed.2019.07.014
172. Ferris LM*, **Saloner B**, Krawczyk N*, et al. Predicting Opioid Overdose Deaths Using Prescription Drug Monitoring Program Data. *Am J Prev Med*. 2019;57(6):e211-e217. doi:10.1016/j.amepre.2019.07.026
173. **Saloner B**, Dague L, Friedsam D, Voskuil K, Serna Borrero N, Burns M. Access to Care Among Individuals Who Experienced Medicaid Lockouts After Premium Nonpayment. *JAMA Netw Open*. 2019;2(11):e1914561. doi:10.1001/jamanetworkopen.2019.14561

174. Lin L-K, Simon K, Hollingsworth A, **Saloner B**⁺. Association Between the Number of Certified Buprenorphine Prescribers and the Quantity of Buprenorphine Prescriptions: Evidence from 2015 to 2017. *J Gen Intern Med*. 2019;34(11):2313-2315. doi:10.1007/s11606-019-05165-6
175. Chang H-Y, Daubresse M*, **Saloner B**, Alexander GC. Chronic Disease Medication Adherence After Initiation of Buprenorphine for Opioid Use Disorder. *Med Care*. 2019;57(9):667-672. doi:10.1097/MLR.0000000000001165
176. Chang H-Y, Krawczyk N*, Schneider KE* ... **Saloner B**⁺. A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients. *Drug Alcohol Depend*. 2019;201:127-133. doi:10.1016/j.drugalcdep.2019.04.016
177. Beetham T, **Saloner B**, Wakeman SE, Gaye M, Barnett ML. Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality: An Audit Study. *Ann Intern Med*. 2019;171(1):1-9. doi:10.7326/M18-3457
178. Eisenberg MD, **Saloner B**, Krawczyk N*, et al. Use of Opioid Overdose Deaths Reported in One State's Criminal Justice, Hospital, and Prescription Databases to Identify Risk of Opioid Fatalities. *JAMA Intern Med*. 2019;179(7):980-982. doi:10.1001/jamainternmed.2018.8757
179. Koyawala N*, Landis R*, Barry CL, Stein BD, **Saloner B**⁺. Changes in Outpatient Services and Medication Use Following a Non-fatal Opioid Overdose in the West Virginia Medicaid Program. *J Gen Intern Med*. 2019;34(6):789-791. doi:10.1007/s11606-018-4817-8
180. Wen H, **Saloner B**, Cummings JR. Behavioral And Other Chronic Conditions Among Adult Medicaid Enrollees: Implications For Work Requirements. *Health Aff (Millwood)*. 2019;38(4):660-667. doi:10.1377/hlthaff.2018.05059
181. **Saloner B**, Landis R*, Stein BD, Barry CL. The Affordable Care Act In The Heart Of The Opioid Crisis: Evidence From West Virginia. *Health Aff (Millwood)*. 2019;38(4):633-642. doi:10.1377/hlthaff.2018.05049
182. **Saloner B**, Wilk AS, Wissoker D, et al. Changes in primary care access at community health centers between 2012/2013 and 2016. *Health Serv Res*. 2019;54(1):181-186. doi:10.1111/1475-6773.13082
183. **Saloner B**, Barry CL. Changes in spending and service use after a state autism insurance mandate. *Autism*. 2019;23(1):167-174. doi:10.1177/1362361317728205
184. Maclean JC, **Saloner B**. The Effect of Public Insurance Expansions on Substance Use Disorder Treatment: Evidence from the Affordable Care Act. *J Policy Anal Manage*. 2019;38(2):366-393.
185. **Saloner B**, McGinty EE, Beletsky L, et al. A Public Health Strategy for the Opioid Crisis. *Public Health Rep*. 2018;133(1_suppl):24S-34S. doi:10.1177/0033354918793627
186. Miclette MA, Leff JA, Cuan I, Samet JH, **Saloner B**, et al. Closing the gaps in opioid use disorder research, policy and practice: conference proceedings. *Addict Sci Clin Pract*. 2018;13(1):22. doi:10.1186/s13722-018-0123-3
187. Bachhuber MA, **Saloner B**, LaRochelle M, et al. Physician Time Burden Associated with Querying Prescription Drug Monitoring Programs. *Pain Med*. 2018;19(10):1952-1960. doi:10.1093/pm/pny053
188. Samples H*, Bandara S*, Olfson M, **Saloner B**⁺. Tobacco Screening and Counseling in the U.S.: Smokers With Mental Health and Substance Use Problems. *Am J Prev Med*. 2018;55(4):524-532. doi:10.1016/j.amepre.2018.05.024

189. Bandara SN*, Samples H*, Crum RM, **Saloner B**⁺. Is screening and intervention associated with treatment receipt among individuals with alcohol use disorder? Evidence from a national survey. *J Subst Abuse Treat.* 2018;92:85-90. doi:10.1016/j.jsat.2018.06.009
190. **Saloner B**, Levin J*, Chang H-Y, Jones C, Alexander GC. Changes in Buprenorphine-Naloxone and Opioid Pain Reliever Prescriptions After the Affordable Care Act Medicaid Expansion. *JAMA Netw Open.* 2018;1(4):e181588. doi:10.1001/jamanetworkopen.2018.1588
191. **Saloner B**, Stoller KB, Alexander GC. Moving Addiction Care to the Mainstream - Improving the Quality of Buprenorphine Treatment. *N Engl J Med.* 2018;379(1):4-6. doi:10.1056/NEJMp1804059
192. Roberts AW, **Saloner B**, Dusetzina SB. Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015. *Psychiatr Serv.* 2018;69(7):832-835. doi:10.1176/appi.ps.201700315
193. **Saloner B**, Hempstead K, Rhodes K, Polsky D, Pan C, Kenney GM. Most Primary Care Physicians Provide Appointments, But Affordability Remains A Barrier For The Uninsured. *Health Aff (Millwood).* 2018;37(4):627-634. doi:10.1377/hlthaff.2017.0959
194. Candon M, Zuckerman S, Wissoker D, **Saloner B**, et al. Declining Medicaid Fees and Primary Care Appointment Availability for New Medicaid Patients. *JAMA Intern Med.* 2018;178(1):145-146. doi:10.1001/jamainternmed.2017.6302
195. **Saloner B**, Akosa Antwi Y, Maclean JC, Cook B. Access to Health Insurance and Utilization of Substance Use Disorder Treatment: Evidence from the Affordable Care Act Dependent Coverage Provision. *Health Econ.* 2018;27(1):50-75. doi:10.1002/hec.3482
196. Maclean JC, **Saloner B**. Substance Use Treatment Provider Behavior and Healthcare Reform: Evidence from Massachusetts. *Health Econ.* 2018;27(1):76-101. doi:10.1002/hec.3484
197. Krawczyk N*, Picher CE*, Feder KA*, **Saloner B**⁺. Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine. *Health Aff (Millwood).* 2017;36(12):2046-2053. doi:10.1377/hlthaff.2017.0890
198. Bachhuber MA, Mehta PK, Faherty LJ, **Saloner B**⁺. Medicaid Coverage of Methadone Maintenance and the Use of Opioid Agonist Therapy Among Pregnant Women in Specialty Treatment. *Med Care.* 2017;55(12):985-990. doi:10.1097/MLR.0000000000000803
199. Cantor J, Stoller KB, **Saloner B**⁺. The response of substance use disorder treatment providers to changes in macroeconomic conditions. *J Subst Abuse Treat.* 2017;81:59-65. doi:10.1016/j.jsat.2017.07.005
200. Krawczyk N*, Feder KA*, Fingerhood MI, **Saloner B**⁺. Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. *Drug Alcohol Depend.* 2017;178:512-518. doi:10.1016/j.drugalcdep.2017.06.009
201. **Saloner B**, Daubresse M*, Caleb Alexander G. Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population. *Med Care.* 2017;55(7):669-676. doi:10.1097/MLR.0000000000000727
202. **Saloner B**, Cope LC, Hempstead K, Rhodes KV, Polsky D, Kenney GM. Price Transparency in Primary Care: Can Patients Learn About Costs When Scheduling an Appointment? *J Gen Intern Med.* 2017;32(7):815-821. doi:10.1007/s11606-017-4003-4

203. Riggs KR*, Ubel PA, **Saloner B**⁺. Can Appealing to Patient Altruism Reduce Overuse of Health Care Services? An Experimental Survey. *J Gen Intern Med*. 2017;32(7):732-738. doi:10.1007/s11606-017-4002-5
204. **Saloner B**, Bandara S*, Bachhuber M, Barry CL. Insurance Coverage and Treatment Use Under the Affordable Care Act Among Adults With Mental and Substance Use Disorders. *Psychiatr Serv*. 2017;68(6):542-548. doi:10.1176/appi.ps.201600182
205. Krawczyk N*, Feder KA*, **Saloner B**, Crum RM, Kealhofer M, Mojtabai R. The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a U.S. national sample. *Drug Alcohol Depend*. 2017;175:157-163. doi:10.1016/j.drugalcdep.2017.02.006
206. Feder KA*, Krawczyk N*, **Saloner B**⁺. Medication-Assisted Treatment for Adolescents in Specialty Treatment for Opioid Use Disorder. *J Adolesc Health*. 2017;60(6):747-750. doi:10.1016/j.jadohealth.2016.12.023
207. Daubresse M*, **Saloner B**, Pollack HA, Alexander GC. Non-buprenorphine opioid utilization among patients using buprenorphine. *Addiction*. 2017;112(6):1045-1053. doi:10.1111/add.13762
208. Boudreaux MH, Gonzales G, **Saloner B**⁺. Medical Financial Burden Declined For Consumers In The Nongroup Market. *Health Aff (Millwood)*. 2017;36(5):833-837. doi:10.1377/hlthaff.2016.1480
209. Wherry LR, Fabi R*, Schickedanz A, **Saloner B**. State And Federal Coverage For Pregnant Immigrants: Prenatal Care Increased, No Change Detected For Infant Health. *Health Aff (Millwood)*. 2017;36(4):607-615. doi:10.1377/hlthaff.2016.1198
210. Polsky D, Candon M, **Saloner B**, et al. Changes in Primary Care Access Between 2012 and 2016 for New Patients With Medicaid and Private Coverage. *JAMA Intern Med*. 2017;177(4):588-590. doi:10.1001/jamainternmed.2016.9662
211. **Saloner B**, Bandara S*, Bacchhuber M, Barry CL. An Update on "Insurance Coverage and Treatment Use Under the Affordable Care Act Among Adults With Mental and Substance Use Disorders". *Psychiatr Serv*. 2017;68(3):310-311. doi:10.1176/appi.ps.201600566
212. Candon M, Polsky D, **Saloner B**, et al. Primary Care Appointment Availability and the ACA Insurance Expansions. *LDI Issue Brief*. 2017;21(5):1-4.
213. **Saloner B**, Bachhuber M, Barry CL. Physicians as a Source of Medications for Nonmedical Use: Comparison of Opioid Analgesic, Stimulant, and Sedative Use in a National Sample. *Psychiatr Serv*. 2017;68(1):56-62. doi:10.1176/appi.ps.201500245
214. Nathenson RA, **Saloner B**, Richards MR, Rhodes KV. Spanish-Speaking Immigrants' Access to Safety Net Providers and Translation Services Across Traditional and Emerging US Destinations. *Milbank Q*. 2016;94(4):768-799. doi:10.1111/1468-0009.12231
215. Fabi R*, **Saloner B**. Covering Undocumented Immigrants - State Innovation in California. *N Engl J Med*. 2016;375(20):1913-1915. doi:10.1056/NEJMp1609468
216. McGinty EE, Samples H*, Bandara SN*, **Saloner B**, Bachhuber MA, Barry CL. The emerging public discourse on state legalization of marijuana for recreational use in the US: Analysis of news media coverage, 2010-2014. *Prev Med*. 2016;90:114-120. doi:10.1016/j.ypmed.2016.06.040

217. Bassey S*, **Saloner B**, Kenney GM, Wissoker D, Polsky D, Rhodes KV. Primary Care Appointment Availability for Medicaid Patients: Comparing Traditional and Premium Assistance Plans. *Med Care*. 2016;54(9):878-883. doi:10.1097/MLR.0000000000000573
218. Powell V*, **Saloner B**, Sabik LM. Cost Sharing in Medicaid: Assumptions, Evidence, and Future Directions. *Med Care Res Rev*. 2016;73(4):383-409. doi:10.1177/1077558715617381
219. **Saloner B**, Stoller KB, Barry CL. Medicaid Coverage for Methadone Maintenance and Use of Opioid Agonist Therapy in Specialty Addiction Treatment. *Psychiatr Serv*. 2016;67(6):676-679. doi:10.1176/appi.ps.201500228
220. **Saloner B**, Bandara SN*, McGinty EE, Barry CL. Justice-Involved Adults With Substance Use Disorders: Coverage Increased But Rates Of Treatment Did Not In 2014. *Health Aff (Millwood)*. 2016;35(6):1058-1066. doi:10.1377/hlthaff.2016.0005
221. **Saloner B**, Sharfstein J. A Stronger Treatment System for Opioid Use Disorders. *JAMA*. 2016;315(20):2165-2166. doi:10.1001/jama.2016.3674
222. **Saloner B**, Gresenz CR. Health Care Experiences of Latino Children in Emerging and Traditional Destinations. *Med Care*. 2016;54(5):442-448. doi:10.1097/MLR.0000000000000504
223. Richards MR, **Saloner B**, Kenney GM, Rhodes KV, Polsky D. Availability of New Medicaid Patient Appointments and the Role of Rural Health Clinics. *Health Serv Res*. 2016;51(2):570-591. doi:10.1111/1475-6773.12334
224. **Saloner B**, Hochhalter S, Sabik L. Medicaid and CHIP Premiums and Access to Care: A Systematic Review. *Pediatrics*. 2016;137(3):e20152440. doi:10.1542/peds.2015-2440
225. Kreider AR*, French B, Aysola J, **Saloner B**, Noonan KG, Rubin DM. Quality of Health Insurance Coverage and Access to Care for Children in Low-Income Families. *JAMA Pediatr*. 2016;170(1):43-51. doi:10.1001/jamapediatrics.2015.3028
226. **Saloner B**, Karthikeyan S*. Changes in Substance Abuse Treatment Use Among Individuals With Opioid Use Disorders in the United States, 2004-2013. *JAMA*. 2015;314(14):1515-1517. doi:10.1001/jama.2015.10345
227. Leininger LJ, **Saloner B**⁺, Wherry LR. Predicting high-cost pediatric patients: derivation and validation of a population-based model. *Med Care*. 2015;53(8):729-735. doi:10.1097/MLR.0000000000000391
228. Friedman AB, **Saloner B**, Hsia RY. No Place to Call Home--Policies to Reduce ED Use in Medicaid. *N Engl J Med*. 2015;372(25):2382-2385. doi:10.1056/NEJMp1502627
229. **Saloner B**, McGinty EE, Barry CL. Policy strategies to reduce youth recreational marijuana use. *Pediatrics*. 2015;135(6):955-957. doi:10.1542/peds.2015-0436
230. **Saloner B**, Polsky D, Kenney GM, Hempstead K, Rhodes KV. Most Uninsured Adults Could Schedule Primary Care Appointments Before The ACA, But Average Price Was \$160. *Health Aff (Millwood)*. 2015;34(5):773-780. doi:10.1377/hlthaff.2014.1258
231. **Saloner B**, Polsky D, Friedman A, Rhodes K. Primary care appointment availability and preventive care utilization: evidence from an audit study. *Med Care Res Rev*. 2015;72(2):149-167. doi:10.1177/1077558715569541
232. Bachhuber MA, **Saloner B**, Barry CL. What ecologic analyses cannot tell us about medical marijuana legalization and opioid pain medication mortality--reply. *JAMA Intern Med*. 2015;175(4):656-657. doi:10.1001/jamainternmed.2014.8027
233. **Saloner B**, Rhodes KV, Polsky D. Access to primary care in England--reply. *JAMA Intern Med*. 2015;175(3):467-468. doi:10.1001/jamainternmed.2014.7871

234. **Saloner B**, Matone M, Kreider AR*, et al. Second-generation antipsychotic use among stimulant-using children, by organization of medicaid mental health. *Psychiatr Serv*. 2014;65(12):1458-1464. doi:10.1176/appi.ps.201300574
235. Bachhuber MA, **Saloner B**, Cunningham CO, Feingold J, Barry CL. Could Delaware's medical marijuana law reduce harms from opioid analgesics? *Del Med J*. 2014;86(11):341-343.
236. Bachhuber MA, **Saloner B**, Cunningham CO, Barry CL. Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. *JAMA Intern Med*. 2014;174(10):1668-1673. doi:10.1001/jamainternmed.2014.4005
237. Richards MR, **Saloner B**, Kenney GM, Rhodes K, Polsky D. Access points for the underserved: primary care appointment availability at federally qualified health centers in 10 States. *Med Care*. 2014;52(9):818-825. doi:10.1097/MLR.0000000000000184
238. **Saloner B**, Cook BL. An ACA provision increased treatment for young adults with possible mental illnesses relative to comparison group. *Health Aff (Millwood)*. 2014;33(8):1425-1434. doi:10.1377/hlthaff.2014.0214
239. **Saloner B**, Carson N, Cook BL. Explaining racial/ethnic differences in adolescent substance abuse treatment completion in the United States: a decomposition analysis. *J Adolesc Health*. 2014;54(6):646-653. doi:10.1016/j.jadohealth.2014.01.002
240. **Saloner B**, Carson N, Cook BL. Episodes of mental health treatment among a nationally representative sample of children and adolescents. *Med Care Res Rev*. 2014;71(3):261-279. doi:10.1177/1077558713518347
241. Rhodes KV, Kenney GM, Friedman AB, **Saloner B**, et al. Primary care access for new patients on the eve of health care reform. *JAMA Intern Med*. 2014;174(6):861-869. doi:10.1001/jamainternmed.2014.20
242. **Saloner B**, Koyawala N*, Kenney GM. Coverage for low-income immigrant children increased 24.5 percent in states that expanded CHIPRA eligibility. *Health Aff (Millwood)*. 2014;33(5):832-839. doi:10.1377/hlthaff.2013.1363
243. **Saloner B**, Sabik L, Sommers BD. Pinching the poor? Medicaid cost sharing under the ACA. *N Engl J Med*. 2014;370(13):1177-1180. doi:10.1056/NEJMp1316370
244. **Saloner B**, Fullerton C, McGuire T. The impact of long-acting medications on attention-deficit/hyperactivity disorder treatment disparities. *J Child Adolesc Psychopharmacol*. 2013;23(6):401-409. doi:10.1089/cap.2012.0019
245. **Saloner B**. Does expanding public insurance prevent material hardship for families with children? *Med Care Res Rev*. 2013;70(3):267-286. doi:10.1177/1077558712470566
246. **Saloner B**, Le Cook B. Alcohol and drug use: the authors reply. *Health Aff (Millwood)*. 2013;32(3):630. doi:10.1377/hlthaff.2013.0094
247. **Saloner B**, Le Cook B. Blacks and Hispanics are less likely than whites to complete addiction treatment, largely due to socioeconomic factors. *Health Aff (Millwood)*. 2013;32(1):135-145. doi:10.1377/hlthaff.2011.0983
248. Gresenz CR, Blanchard JC, Timbie JW, et al. Behavioral Health in the District of Columbia: Assessing Need and Evaluating the Public System of Care. *Rand Health Q*. 2012;2(1):14.
249. **Saloner B**, Daniels N. The ethics of the affordability of health insurance. *J Health Polit Policy Law*. 2011;36(5):815-827. doi:10.1215/03616878-1407631

250. Keating EG, Brauner MK, Galway LA, Mele JD, Burks JJ, **Saloner B**. The Air Force Medical Corps' status and how its physicians respond to multiyear special pay. *Mil Med*. 2009;174(11):1155-1162. doi:10.7205/milmed-d-01-4309
251. Daniels N, **Saloner B**, Gelpi AH. Access, cost, and financing: achieving an ethical health reform. *Health Aff (Millwood)*. 2009;28(5):w909-916. doi:10.1377/hlthaff.28.5.w909

Chapters

1. **Saloner, B**. Alcohol and Other Drugs: Public Health Ethics Issues. In *The Oxford Handbook of Public Health Ethics*. Oxford: Oxford University Press. 2019.
2. **Saloner, B**, Gibbons J*. Access to Treatment for Opioid Use Disorder. In *The Oxford Handbook on Opioid Use Disorder*. Oxford: Oxford University Press. Forthcoming.

Articles, Editorials and Other Publications Not Peer Reviewed

1. **Saloner B**, Blumenthal-Barby J. Coercion, Power Relations, and the Expectations Patients Bring to Mental Health Treatment. *Am J Bioeth*. 2024;24(12):6-7. doi:10.1080/15265161.2024.2420560
2. Turnbull AE, Bouhassira DC, **Saloner B**. Incapacitated and Incarcerated-Double Barriers to Care. *JAMA Intern Med*. 2024;184(1):35-36. doi:10.1001/jamainternmed.2023.6067
3. Allen L, Burns MB, **Saloner B**. The consequences of removing prior authorization for buprenorphine in Medicaid: Building an evidence base. *JAMA Health Forum*. 2022;3(6):e220189. doi:10.1001/jamahealthforum.2022.0189
4. **Saloner B**, Feder KA*, Krawczyk N*. Closing the Medication-Assisted Treatment Gap for Youth With Opioid Use Disorder. *JAMA Pediatr*. 2017;171(8):729-731. doi:10.1001/jamapediatrics.2017.1269
5. **Saloner B**. Medicaid Expansion, Chronic Disease, and the Next Chapter of Health Reform. *J Gen Intern Med*. 2018;33(3):243-244. doi:10.1007/s11606-017-4262-0
6. **Saloner B**. Commentary on Kertesz & Gordon (2019): Don't abandon opioid prescription control efforts, reform them. *Addiction*. 2019;114(1):181-182. doi:10.1111/add.14422

PRACTICE ACTIVITIES

Practice-Related Reports

1. Feder KA, Byrne L, Miller SM, Sodder S, Berman V, Livingston A, Edwards J, Hartman S, Harris SJ, Sugarman OK, Shah H, Xu J, Raikes J, Gattine S, Stuart EA, **Saloner B**. Evaluation of a Vermont Law Eliminating State Criminal Penalties for Possessing 224 Milligrams or Less of Buprenorphine. *Johns Hopkins Bloomberg American Health Initiative*, 2023.
2. Rising J, Whaley S, **Saloner B**. How the Drug Enforcement Administration Can Improve Access to Methadone in Correctional Facilities. *Johns Hopkins Bloomberg American Health Initiative*. 2022.
3. In Their Own Words: Experiences of People Who Use Drugs During the COVID-19 Pandemic. *Johns Hopkins Bloomberg American Health Initiative*. 2022.
4. Large-Scale New Jersey Prison Releases During COVID-19. *Johns Hopkins Bloomberg American Health Initiative*. 2021.
5. Medications for Opioid Use Disorder in Jails and Prisons: Moving Toward Universal Access. *Johns Hopkins Bloomberg American Health Initiative*. 2021.

6. Committee on a National Strategy for Ensuring Cancer Control. *Guiding Cancer Control: A Path to Transformation* (listed as consultant). Washington, DC: National Academies Press, 2019.
7. Association of Schools and Programs in Public Health. *Bringing Evidence to Bear on Opioids* (listed as contributing author). Washington, DC: ASPPH, 2019.
8. **Saloner B**, Bachhuber M, Barry CL, Krawczyk N, Pasha O, Sen AP, Sharfstein J. *A Blueprint for Transforming Opioid Use Disorder Treatment in Delaware*. Baltimore, MD: Johns Hopkins Bloomberg School of Public Health, 2018.
9. Committee on Ensuring Patient Access to Affordable Drug Therapies. *Making Medicines Affordable: A National Imperative* (listed as contributing author). Washington, DC: National Academies Press, 2018.
10. Candon, M., Polsky, D., **Saloner, B.**, Wissoker, D., Hempstead, K., Kenney, G.M. and Rhodes, K., *Primary Care Appointment Availability and the ACA Insurance Expansions*. LDI Issue Brief. Philadelphia, University of Pennsylvania, 2017.
11. Committee on Accounting for Social Risk Factors in Medicare Payment (listed as contributing author). *Accounting for Social Risk Factors in Medicare Payment: Identifying Social Risk Factors*. Washington, DC: National Academies Press, 2016.
12. Committee on Accounting for Social Risk Factors in Medicare Payment (listed as contributing author). *Accounting for Social Risk Factors in Medicare Payment: Criteria, Factors, and Methods*. Washington, DC: National Academies Press, 2016.
13. **Saloner B**, Kenney GM, Polsky D, Rhodes KV, Wissoker D, Zuckerman S. The Availability of New Patient Appointments for Primary Care at Federally Qualified Health Centers: Findings From an Audit Study. Washington, DC: Urban Institute, 2014.
14. Kenney GM, **Saloner B**, Anderson N, Polsky D, Rhodes KV. Access to Care for Low-Income Medicaid and Privately-Insured Adults in 2012 in the National Health Interview Survey: A Context for Findings from a New Audit Study. Washington, DC: Urban Institute, 2014.
15. Gresenz CR, Blanchard JC, Timbie JW, Acosta JD, Pollack CE, Ruder T, **Saloner B**, Benjamin-Johnson R, Weinick RM, Adamson DM, Hair B. Behavioral Health in the District of Columbia: Assessing Need and Evaluating the Public System of Care. TR-914-DCDMH. Santa Monica, CA: RAND Corporation. 2010.
16. Acosta JD, Blanchard JC, Pollack CE, Benjamin-Johnson R, Adamson DM, Gresenz CR, **Saloner B**. Guide to the Behavioral Health Care System in the District of Columbia. WR-777. Santa Monica, CA: RAND Corporation, 2010.
17. Keating EG, Brauner MK, Galway LA, Mele JD, Burks JJ, **Saloner B**. Air Force Physician and Dentist Multiyear Bonuses: Current Status and Potential Reforms. MG-866-AF. Santa Monica, CA: RAND Corporation. 2008.
18. Finegold K, Kramer FD, **Saloner B**, Parnes JH. The Role of the Commodity Supplemental Food Program (CSFP) in Nutritional Assistance to Mothers, Infants, and Seniors. Contractor and Cooperator Report #48. Washington, DC: Economic Research Services, United States Department of Agriculture. 2008.
19. Kramer FD, Castaneda RM, **Saloner B**, Finegold K. Studying the Consequences of Hurricane Katrina for ACF Service Populations: Annotated Bibliography. Washington, DC: Urban Institute. 2007.

Association for Schools and Programs in Public Health Task Force 2018-2019

The ASPPH has convened a task force of public health experts to develop recommendations for addressing the opioid crisis. This task force is meeting regularly to discuss public health frameworks, evidence, and interventions that may be beneficial. It is also tasked with providing guidance to a judge overseeing litigation related to opioids.

Technical Advisor to the Government of Delaware, 2017-2018

Working with the leadership in the Department of Health and Social Services (DHSS), I led a team of experts to formulate recommendations to improve access and quality of treatment for individuals with opioid use disorder in Delaware. This includes creating a comprehensive report, briefing senior agency staff in DHSS and other government agencies, and meeting with stakeholders throughout the state.

National Academy of Medicine Fellow in Bioethics, 2016-2017

Participated in the intellectual development of consensus studies working with the staff of the National Academy of Medicine and with members of consensus committees. In 2016, worked with the committee on Accounting for Social Risk Factors in Medicare Payment. In 2017, I worked with the committee on Protecting Patient Access to Affordable Drugs.

Bloomberg American Health Initiative, 2016-2025

The Bloomberg American Health Initiative represents a \$330 million gift from Bloomberg Philanthropies to Johns Hopkins School of Public Health to develop interdisciplinary programs focused on teaching, research, and advocacy around five problems of national importance. I co-lead (with Dr. Susan Sherman) a workgroup focused on Addiction and Overdose. We are responsible for developing new programs to fulfill the Bloomberg American Health Initiative mission, working with individuals across the school of public health. In 2017, our group began admissions for the MPH program and we launched the DrPH program in 2018. In 2018, our group held a key stakeholder symposium that lasted 1.5 days and attracted national leaders.

Research Finding Dissemination

Participated in briefing with Congressional Staffers on Medicaid fees (2015)

Briefing to Delaware Department of Health and Social Services on opioid treatment strategy report (2018)

Briefing to the US Surgeon General on public health strategies related to opioids (2018)

Briefings to US Members of Congress at Johns Hopkins (2019)

Briefings to the DEA Administrator and her staff (2021, 2022)

COVID-19 in Jails and Prisons, Webinar to the Public (2022)

Congressional Briefing Series: Programmatic and Treatment Efforts to Combat the Opioid Epidemic (2023)

US Senate Finance Committee, Health Care Subcommittee, Hearing, “Closing Gaps in the Care Continuum: Opportunities to Improve Substance Use Disorder Care in the Federal Health Programs” (April 9, 2024)

Selected Media Mentions

New York Times, NPR, Washington Post, Vox, Time, PolitiFact, Wired, Reuters, Medscape, Healthline, Vice, BBC, the Huffington Post, The Boston Globe, Business Insider, the Associated Press, BuzzFeed News, WBUR, NPR.

PART II

TEACHING

Faculty Mentoring

Faculty mentor to Assistant Scientist Alexander McCourt, January 2019-July 2021

Doctoral Advising

Primary advisor:

Sage Feltus (Brown University), September 2026 –

Hridika Shah, PhD student, August 2024 – July 2025

Rosemary Laine, PhD student, August 2023 – July 2025

Emily Borgelt, DrPH Student, August 2021 – July 2025

Julie Rwan, DrPH Student, August 2021 – July 2025

Lia Pizzicato, DrPH student, August 2021 – July 2025

Theodore Schall, PhD Student, Fall 2019 – May 2023 (joint advisee with Nancy Kass)

Thesis Title: “Insurance Coverage of Gender Affirming Care for Transgender Adults”

Christian Morales, PhD Candidate, Fall 2015—June 2021 (joint advisee with Nancy Kass)

Thesis Title: “Measuring Disability Related Health Disparities: Empirical and Normative Issues”

Jonathan Levin, PhD Candidate, Fall 2016 – May 2020

Thesis Title: “Promoting Access to Hepatitis C Treatment: Policies and their Impacts on Patients and Society.”

Hillary Samples, PhD Candidate (joint advisee with Colleen Barry), Fall 2013 – June 2017

Thesis Title: “Health Care for Common Mental Illness: The Impact of National Insurance Reform on Utilization and Spending and a Study of Services Provided in General Medical Settings.”

Committee member:

Isha Desai (proposal, final defense) 2026

Brandon Park (University of Missouri, St. Louis) (Specialty paper) 2026

Valerie Ganetsky, 2024 (departmental, schoolwide)

Jirka Taylor, 2024 (departmental, schoolwide)

Brittain Brantley, 2024 DrPH (departmental, schoolwide)

Caren Steinway, 2024 DrPH (schoolwide)

Aisha Ellis, 2024 (School of nursing, preliminary exam)

Abigail Winiker, 2022 (Schoolwide)

Alexandra Ruth, PhD student (departmental, schoolwide, and final thesis defense)

Rachel Landis, PhD, George Washington University Trachtenberg School, graduated 2022 (schoolwide committee and final thesis defense)

Kristin Schneider, PhD candidate, graduated 2020 (schoolwide committee)

Lindsey Ferris, DrPH candidate, graduated 2019 (departmental, and final thesis defense)

Noa Krawczyk, PhD candidate, graduated 2019 (schoolwide committee, and final thesis defense)

Sachini Bandara, PhD candidate, graduated 2018 (departmental, schoolwide)

Samya Mamari, DrPH candidate, graduated 2018 (final thesis defense)

Rachel Fabi, PhD candidate, graduated 2017 (departmental, schoolwide, and final thesis defense)

Leila Jamal, PhD candidate, graduated 2017 (departmental, schoolwide, and final thesis defense)

Shani Buggs, PhD candidate, graduated 2018 (departmental)
Sangeetha Malaiyandi, PhD candidate (schoolwide committee)

Other Mentees and Advisees

Exploratory Network Advisor (Academic Advisor to 6 Brown Freshmen) 2025-2027

Zimani Betts (MPH student), 2023-2025
Bridget Duffy (MPH student), 2023-2025
Adrienne Sanders (MPH student), 2023-2025
Misch Whitaker (MPH student), 2023-2025
Clement Chen (MPH students), 2023-2025
Callie Kelly (MPH student), 2022-2025
Hannah Lessels (MPH student), 2022-2025
Jaime Metzger (MPH student) 2022-2025
River Rose (MPH student) 2022-2025
Wren Ronan (MPH student) 2022-2025
Zachary Sartor (MPH student) 2022-2025
Lumin Shen (MHA student) 2020-2021
Daniel Schwartz (MPH student) 2021-2023
Jen Black (MPH student) 2021-2023
Sarah Windels (MPH student) 2021-2024
Michelle Gaffeney (MPH student) 2021-2024
Stephanie Grube (MPH student) 2019-2020
Rachel Alinsky (research mentor, Adolescent medicine fellow) 2019-2021
Nicholas Misera (part-time MPH student) 2019-2022
Eric Choi (MPH student) 2018-2020
Madeleine O'Neill (MPH student capstone advisor) 2018-2019
Hannah Johnson (MPH student/Bloomberg Fellow) 2018-2020
Andrea Walker (MPH student/Bloomberg Fellow) 2017-2021
Jerilyn Hoover, (part-time MPH Student) 2017-2020
Eva Lenoir, (MPH Student) 2017-2019
Halle Martello, (MPH student) Continuing in 2017-2020
Tess Donckels (MSPH student) 2017-2019
Lindsay Wang (MPP student) 2016-2018
Jingwen Ye (MPP student) 2016-2018
Kyla Ellis (MPH/MBA student) 2015-2017
B. Marie Ward (part-time MPH student) 2015-
Megan Collins (part-time MPH student) 2015-2017
Caroline Picher (MPH student, capstone advisor) 2016 (Received award for outstanding capstone project)
Neel Koyawala (summer undergraduate research "SUMR", program mentee, University of Pennsylvania) 2013; (as a medical student at Johns Hopkins) 2018

Classroom Instruction

Primary Instructor, “*Foundational Readings in Health Policy: Theories, Frameworks, and Multidisciplinary Perspectives for Research and Practice*”

(First year seminar for doctoral students in health policy and management)

Baltimore, MD

(Terms 2-3, 2017-2018, 2018-2019, 2020-2021, 2021-2022; Terms 1-3: 2022-2023, 2023-2024, 2024-2025)

Instructor, “*Social Justice Theory: US and European Perspectives.*”

Johns Hopkins Twelfth Annual Fall Institute in Health Policy and Management, Barcelona, Spain. (November 2015)

Instructor, “Managerial Health Economics,” Strathmore University MBA Program, Nairobi Kenya (September 2014; May 2015)

RESEARCH GRANT PARTICIPATION CURRENT

Convening New England Leaders to Develop Collaborative Opioid Data Capacity

7/15/2026-1/14/2027, FORE Foundation

Role Principal Investigator, \$32,437

This project convenes academics, government leaders, and nonprofit organizations from Connecticut, Massachusetts, and Rhode Island to develop a collaborative data strategy to address the opioid epidemic in the three states.

Improving the Quality of Emergency Care for Opioid Overdose Survivors

12/1/2025-11/30/2027, FORE Foundation

Role co-Investigator (PIs Sachini Bandara and Matthew Eisenberg) \$595,878

Researchers at Johns Hopkins Bloomberg School of Public Health will map the extent to which emergency departments and emergency medical services (EMS) initiate buprenorphine, as well as identify the policy and system-level factors that would increase the uptake of these evidence-based practices. The resulting toolkit and policy recommendations will be targeted to accrediting bodies, payers, state health departments, and hospital associations. The researchers will also document whether and how Medicaid programs across the U.S. pay for EMS-initiated buprenorphine.

Evaluating a Novel Approach to Dispensing Methadone in Carceral Facilities (R01DA064510)

9/1/25-31/5/2030, National Institute on Drug Abuse

Role co-Principal Investigator (with Sachini Bandara), \$3,443,149

In 2024, a federal rule clarified that carceral facilities licensed as hospital/clinics can dispense methadone outside of the traditional opioid treatment program structure. In this project, we will work closely with departments of corrections in Colorado, Delaware, and Washington state that

are expanding methadone access using this new provision. Aim 1 launches a learning collaborative with an embedded implementation study. The three vanguard state prison systems and several other jail and prison systems that are planning to implement the hospital/clinic designation will participate in a 24-month program. Aim 2 will analyze electronic records on persons who have diagnosed OUD from each system spanning 2022 to 2028. Using a trial emulation study design that considers the impact of a facility starting to stock methadone under the hospital/clinic designation, we will evaluate how the rollout of new services in the three state prison systems affects pre-release initiation and retention on MOUD. Linking carceral records to Medicaid claims, Aim 3 will extend the same trial emulation framework in Washington State to study the impact on post-release outcomes such as MOUD and avoidable hospitalizations. Finally, using measures of spending, resources and staffing, and health impacts collected in Aims 1-3, Aim 4 will examine the associated costs, cost effectiveness, and budgetary impact of phasing in the hospital/clinic designation.

The Effects of Zero Cost-Sharing on Mental Health Services Outcomes (R01MH135530)

4/1/24-1/31/28, National Institute of Mental Health
Role co-investigator (PI Ezra Golberstein)

Costs of care and concerns about affordability are among the most prominent barriers to mental health services, even among Americans with commercial health insurance. The state of New Mexico passed a law (SB 317) to eliminate cost-sharing for mental health and substance use disorder services in commercial insurance, in order to improve access to services. The proposed study will use qualitative and quantitative methods to assess how this law is affecting the delivery of mental health services from patient and provider perspectives, and how it is affecting patterns of mental health services use and quality of care.

NY MOVES: Evaluating the Impact of New York's Methadone Outreach VEHicleS (R01DA063711)

5-September-2025- 31-May-2030, National Institute on Drug Abuse

Role co-investigator (PIs Noa Krawczyk, Ashly Jordan),

New federal regulations that allow methadone treatment for opioid use disorder to be delivered via mobile units could transform access to this lifesaving treatment and reduce overdose deaths. Using New York State as a case study of the first statewide effort to expand mobile methadone units, we propose a mixed-methods study to evaluate the impact of the mobile methadone program on health outcomes, patient and provider experiences, and cost considerations that would inform long-term sustainability. Through a unique partnership between academic researchers and New York State government officials, and a national stakeholder engagement and dissemination plan that draws direct input from individuals with living experience on methadone, this work will inform real-world practices that can improve access to treatment, reduce overdose and improve population health across the U.S.

Establishing an Evidence Base to Increase the Utility of Urine Drug Testing in Opioid Use Disorder Treatment (R01DA059528)

6/15/24-3/31/28, National Institute on Drug Abuse

Role co-Principal Investigator (with Alene Kennedy Hendricks), \$2,726,586

Urine drug testing (UDT) is an integral component of opioid use disorder (OUD) treatment, and is often required by payers for patients treated with medications for OUD (MOUD). The goal of this grant is to identify variation in real-world use of UDT that can be modified by clinical guidelines and policy change, and to examine the patient- and clinician-level factors that influence the application of UDT, and their relationship with processes of care. Aim 1 will characterize distinct trajectories of UDT use during episodes of OUD treatment nationally and Aim 2 will identify distinct trajectories of drug positivity during OUD treatment episodes and identify variation across groups. Aim 3 will estimate the association between trajectories of UDT use, substance positivity, and process of care measures in the episode (e.g., retention, MOUD adherence, hospitalization). Aim 4 will examine perspectives of clinicians to identify perceptions and practices related to UDT use.

Impact of a Maryland Law Requiring Jails to Provide Medications for Opioid Use Disorder on Recently Incarcerated People (R01 DA057264)

7/1/23-5/31/27, National Institute on Drug Abuse

Role co-Principal Investigator (with Alene Kennedy Hendricks), \$2,977,684

Increasing access to medications for opioid use disorder could dramatically reduce risk of overdose and other negative health outcomes after release from jail, but these medications are often not available during and after jail stays. In this project, we study the public health impact of a statewide law in Maryland requiring local jails to provide access to medication during incarceration with linkage to care after release. Aims 1 and 2 will analyze a data warehouse that links statewide correctional records, hospital, prescription monitoring program, behavioral health, and medical examiner data. Aim 3 will provide complementary implementation evidence focusing on 8 jails. We will conduct in depth, semi-structured interviews with 40 program leaders (e.g., jail staff, community providers) and 40 formerly incarcerated individuals to explore barriers and facilitators to providing MOUD in jail and post-release.

Greenwall Faculty Scholars

7/1/23-6/30/26, Greenwall Foundation

Role: Principal Investigator, \$417,700

Many people receive addiction treatment under a criminal legal mandate from courts, police, or community corrections. While coerced treatment is generally impermissible in health care because it violates patient autonomy, providers may justify collaborating in mandated treatment as a way to benefit patients who would otherwise face incarceration. This project will develop a novel ethics framework based on qualitative interviews with policymakers, providers, and formerly mandated patients. The grant will support the development of ethics-informed guidelines for programs and providers to manage the ethical tensions of participating in oversight and surveillance of mandated patients.

PRIOR GRANTS

Implementation of Mobile Medication Units for Patients with Opioid Use Disorder in New York (R21DA058117)

9/30/23-8/31/2025, National Institute on Drug Abuse

Role: Principal Investigator, \$245,625

Mobile methadone is a service delivery model that allows vehicles to dispense methadone as an extension of a community opioid treatment program. This project will evaluate the early

implementation of the mobile methadone grant program in New York, where the state has invested in creating new units. The aims include interviews with pilot sites and their community partners, surveys with people who are current or potential mobile unit patients, and the use of geospatial methods to identify communities where there is likely to be high need for mobile services.

Bloomberg Overdose Prevention Initiative

10/1/21-7/1/2025, Bloomberg Philanthropies

Role: Co-Principal Investigator (with Joshua Sharfstein) \$5,000,000

This grant extends the Bloomberg Opioid Initiative, an effort to reduce overdose deaths through technical assistance provided to state and federal government. Johns Hopkins leads the evaluation and research team, in partnership with Vital Strategies, Pew, the CDC, and the CDC Foundation. The Initiative will work in Kentucky, Michigan, New Jersey, New Mexico, North Carolina, Pennsylvania, and Wisconsin.

Rationing Behind Bars: Resource Allocation in Jails and Prisons During COVID-19

1/1/21-12/31/22, Greenwall Foundation

Role: Principal Investigator \$246,449

This grant uses a mixed methods approach to examine the bioethical issues related to resource allocation in carceral settings during the COVID-19 pandemic. The aims include a critical literature review, semi-structured interviews with frontline providers and correctional staff, and interviews with previously incarcerated individuals who were released during the pandemic.

Using Licensure Authority to Increase Access to Medications for Opioid Use Disorder in Specialty Treatment

5/1/20-10/31/22, Arnold Ventures

Role: Principal Investigator \$668,593

This grant will establish and disseminate model substance use disorder treatment program licensure/accreditation policies and build the evidence base for licensure requirements for medications for opioid use disorder (MOUD) treatment in specialty program.

Increasing Access to Evidence-Based Medication Treatment for Opioid Use Disorder among Justice-Involved Individuals

4/1/19-11/1/20 (no-cost extension to 6/31/2021), Arnold Ventures

Role: Principal Investigator \$323,364 (directs)

The goal of this study is to identify policies and practices that could increase access to FDA-approved medications for opioid use disorder among individuals in criminal justice settings. It includes qualitative interviews with sheriffs, wardens, and other correctional officials to understand barriers and facilitators to providing medications for individuals in the justice system and a project to develop a data linkage and evaluation plan to study a program that aims to increase access to medications in the Delaware Department of Correction.

Opioid Policy Tools and Information Center (OPTIC) (1P50DA046351-01)

8/15/18-7/31/23, National Institute on Drug Abuse

Role: Co-investigator (PI: Bradley Stein), \$1,419,620

This center grant is intended to create a national resource for facilitating improved policy analysis related to opioids. I will be most closely involved in the center component related to characterizing changes in state level resources to combat the opioid crisis and in measuring the availability of licit and illicit opioids in areas over time.

Quality of Medication Treatment for Opioid Use Disorder in Medicaid Enrollees: The Effects of State Policies and Initiatives (1R01DA045800-01)

7/1/18-4/30/19, National Institute on Drug Abuse

Role: Co-investigator (PI: Bradley Stein), \$613,917

This project will characterize how medication treatment (MT) use, quality, and related health outcomes for Medicaid-enrollees with opioid use disorders has changed over time, overall, and among historically underserved and high-risk populations. We will examine the extent to which state and federal policies have increased MT use, improved MT quality, and improved related health outcomes, overall, and for historically underserved or high-risk populations.

Evaluation and Technical Assistance of State Opioid Strategies

1/1/19-12/31/22 Bloomberg Philanthropies

PI: Joshua Sharfstein

Role: Lead for Evaluation Component (with Elizabeth Stuart), \$1,100,000

Johns Hopkins Bloomberg School of Public Health will provide evaluation and technical assistance to Bloomberg Philanthropies, Pew, and Vital Strategies for an evaluation of state-level policies and programs being implemented on a rapid cycle related to opioid overdose reduction. I am co-leading the component on evaluation and modeling.

Improving Access and Quality of care for Medicaid-Eligible Adults with Opioid Use Disorder (1K01DA042139-01A1)

4/1/17-3/31/22, National Institute on Drug Abuse

Role: Principal Investigator, \$917,096

This is an early career award that will support research and training related to opioid use disorder treatment for individuals enrolled in the Medicaid program. It includes training related to causal inference, cost effectiveness analysis, spatial modeling, and addiction medicine. The research aims include an analysis of Medicaid claims data from Maryland and West Virginia and survey data from the National Survey on Drug Use and Health.

Past Projects

High Risk Prescription Drug Users

10/01/15-12/31/18, US Department of Justice

Role: Co-Principal Investigator (with Jonathan Weiner), \$500,000

This study aims to develop a predictive risk model for opioid overdose to facilitate timely intervention for vulnerable individuals. It links multiple criminal justice and clinical data systems in Maryland and derives risk scores for individuals observed in these data systems.

Technical Assistance Grant to the State of Delaware to Develop Opioid Treatment Strategy

12/1/17-3/31/18, Delaware Department of Health and Social Services

Role: Principal Investigator, \$50,000

This was a technical assistance grant to assist the Delaware Department of Health identify evidence-based strategies for assisting high-risk populations to access treatment for opioid use disorder. It involved extensive fieldwork and literature reviews.

Lipitz Award for Research on the Impact of the Affordable Care Act on Buprenorphine Treatment

11/1/16-10/31/17, Internal JHSPH award

Role: Principal Investigator, \$10,000

This award supported an original study using pharmacy claims to study the Affordable Care Act Medicaid expansion and to disseminate research findings.

National Academy of Medicine Anniversary Fellow in Bioethics

10/1/15-9/30/17, Greenwall Foundation

Role: Principal Investigator, \$20,000

This award supported participation in the Anniversary Fellowship program at the National Academy of Medicine, including time spent assisting two consensus studies (one on accounting for social risk factors in Medicare payment and one on affordable pharmaceutical drugs).

Evaluation of Medicaid 1115 Coverage Waiver

9/1/15-8/31/17, State of Wisconsin Department of Health Services

Role: Sub-Contracting Principal Investigator, \$210,169

This was an evaluation of the Wisconsin 1115 waiver that was implemented in 2014 and which allowed the state to deviate from traditional Medicaid requirements by imposing greater penalties for non-payment of insurance premiums than previously allowed. The study used claims and enrollment data from the Wisconsin Medicaid program.

The Relationship between Primary Care Appointment Availability and health Services Utilization Among Non-Elderly Adults: A Ten States Study

10/1/12 - 9/1/13, Robert Wood Johnson Health and Society Scholars Program

Role: PI, \$26,900

This grant supported the linkage of commercial insurance claims with data from an experimental audit study that was conducted in ten states.

The Impact of State Mental Health Policies on Trajectories of Children Diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD)

10/1/12 - 9/1/13, Robert Wood Johnson Health and Society Scholars Program

Role: PI, \$18,200

This grant supported research using Medicaid claims data from 83 diverse US counties on children with diagnosed ADHD in order to understand treatment trajectories of these youth.

Access to Health Care for Hispanic Children in Emerging and Traditional Destinations in the United States

10/1/12 - 9/1/13, Robert Wood Johnson Health and Society Scholars Program

Role: PI, \$3,150

This grant supported a study to compare the health care experiences of Hispanic children residing in “emerging” versus “traditional” destinations in the US using restricted survey data linked to county demographic information.

ACADEMIC SERVICE

Schoolwide: Bloomberg School of Public Health

2018 – 2022, Advisory Committee, Bloomberg American Health Committee

2017-18 – Search Committee for Faculty Member at the Berman Institute of Bioethics/

Department of International Health

Department of Health Policy and Management

2023-Current Program Director of the PhD Program in Health Policy and Management

2019-2023 Bioethics PhD Program Committee Director

2021 – Search Committee Member, Search for Chair of Department of Health Policy and Management

2021 – Chair Search Committee for Faculty Member at the Berman Institute of Bioethics/Department of Health Policy and Management

2019-2020 – Chair Search Committee for Faculty Member at the Berman Institute of Bioethics/Department of Health Policy and Management

2018 – Co-Chair (with Nancy Kass) Search Committee for Faculty Member at the Berman Institute of Bioethics/Department of Health Policy and Management

2018-2021 – Bioethics PhD Program Admissions Committee

2017-18– Johns Hopkins Masters in Public Policy (MPP) Review Committee

2016-2019– Johns Hopkins Department of Health Policy & Management Department General Exam Committee

2016 –Johns Hopkins Masters in Public Policy (MPP) Advisory Committee

2016 – Johns Hopkins Health and Public Policy PhD Program Admissions Committee

2016 – Johns Hopkins Bioethics PhD Program Curriculum Review Committee

2015 – Johns Hopkins Masters in Public Policy (MPP) Ad Hoc Strategic Planning Committee

2014 – Johns Hopkins Masters in Public Policy (MPP) Curriculum Review Committee Member

PRESENTATIONS

Scientific Meetings (Oral presentations only)

Symposium on Current Issues in Urine Drug Testing. Addiction Health Services Research Meeting, October 5, 2026. Salt Lake City, Utah.

Mandated Drug Treatment (panelist on roundtable discussion). College on Problems of Drug Dependence, June 25, 2025. New Orleans, LA.

Policy Responses to the Continuing Opioid Overdose Crisis: What Now? (Panelist on roundtable discussion). AcademyHealth Annual Research Meeting. July 1, 2024. Baltimore, MD.

COVID-19 control in carceral settings: Perspectives from correctional leaders and recently incarcerated individuals. AcademyHealth Annual Research Meeting. June 6, 2022. Washington, DC.

Travel Distance and Utilization of Buprenorphine Treatment in West Virginia Medicaid. AcademyHealth Annual Research Meeting. June 4, 2019. Washington, DC.

The Effect of Medicaid Health Homes on Individuals with Behavioral Health Disorders. AcademyHealth Annual Research Meeting. June 4, 2019. Washington, DC.

Buprenorphine and Opioid Pain Reliever Use after the Affordable Care Act Medicaid Expansion. Association for Public Policy and Planning Meeting. November 10, 2018. Washington, DC.

Ensuring Access to Affordable Prescription Drugs—the National Academies of Sciences, Engineering and Medicine’s Report (panelist on roundtable discussion). AcademyHealth Annual Research Meeting. June 24, 2018. Seattle, WA.

Framing the Conversation on the Opioid Epidemic. Robert Wood Johnson Foundation Sharing Knowledge Conference. March 9, 2018. Phoenix, AZ.

The Affordable Care Act in the Heart of the Opioid Epidemic: Evidence from West Virginia. Association for Public Policy and Planning Meeting. November 3, 2017. Chicago, IL.

Do Medicaid Lockouts Affect Enrollment and Access to Care? Evidence from Wisconsin. AcademyHealth Annual Research Meeting. June 27, 2017. New Orleans, LA.

Primary Care Access and Affordability for the Uninsured Before and After the ACA. AcademyHealth Annual Research Meeting. June 27, 2017. New Orleans, LA.

Using Data Science to Identify Individuals at High Risk of Opioid Overdose. Association of Public Policy and Management meeting. November 8, 2016. Washington, DC.

Substance Use Disorder Treatment Among Criminal Justice-Involved Adults: Trends from 2004 to 2014. AcademyHealth Annual Research Meeting. June 27, 2016. Boston, MA.

Price Transparency in Health Care: What Can Consumers Learn When Shopping for a Price? American Society of Health Economics Biennial Meeting. June 14, 2016. Philadelphia, PA.

The Impact of a State Autism Coverage Mandate: Evidence from Kansas. American Society of Health Economics Biennial Meeting. June 14, 2016. Philadelphia, PA.

The Transformation of Specialty Substance Abuse Treatment After Health Care Reform: Evidence from Massachusetts. Addiction Health Services Research Meeting. October 16, 2015. Los Angeles, CA.

The Impact of the ACA Young Adult Provision on Substance Abuse Treatment. Association of Public Policy and Management meeting. November 6, 2014. Albuquerque, NM.

The Impact of the ACA Young Adult Provision on Substance Abuse Treatment. Addiction Health Services Research Meeting. October 16, 2014. Boston, MA.

Access to Primary Care for New Medicaid Patients and Preventive Care Utilization: Evidence from an Audit Study. American Society of Health Economics. June 25, 2014. Los Angeles, CA.

Episodes of Mental Health Treatment Among a Nationally Representative Sample of Children and Adolescents. American Society of Health Economics. June 24, 2014. Los Angeles, CA.

Does Primary Care Access Promote Utilization of Preventive Health Care? Evidence from an Experimental Audit Study. APPAM Annual Meeting. November 9, 2013, Washington, DC.

The Health Care Experiences of Immigrants in New and Traditional Destinations. APPAM Annual Meeting. November 10, 2013, Washington, DC.

Hispanic children's health care experiences in new and traditional destinations. RWJ HSS Annual Meeting, May 8, 2013. San Diego, CA.

Explaining Racial/Ethnic Disparities in Adolescent Substance Abuse Treatment: A Decomposition Analysis. National Hispanic Science Network on Drug Abuse, September 28, 2012, San Diego, CA.

Invited Seminars

The state of federal and state policy related to opioids. FORE Foundation grantee meeting. October 8, 2025.

An Investment Approach to the Opioid Settlement. The National Academies of Sciences, Engineering, and Medicine's Forum on Mental Health and Substance Use Disorders. Effective Models to Address Mental Health and Substance Use Disorders: Strategies for Successful and Equitable Abatement Using Opioid Settlement Dollars. December 5, 2024

Human Rights, Incarceration, and Substance Use Disorders. Human Rights, Professional Ethics and the Values of Medicine Interest Group, National Academy of Medicine. October 20, 2024.

Is legally mandated treatment a blunt but necessary tool in substance use policy? Health Law Seminar, Harvard Law School. October 7, 2024.

A Policy Playbook to Support People at Risk of Overdose. Department of Population Medicine, Harvard Medical School. October 9, 2024.

From Crisis to Opportunity: Touchpoints to Expand Opioid Use Disorder Treatment. Emory School of Public Health Grand Rounds. March 19, 2024.

From Crisis to Opportunity: Touchpoints to Expand Opioid Use Disorder Treatment. Johns Hopkins Department of Psychiatry Grand Rounds. February 27, 2024.

From Crisis to Opportunity: Touchpoints to Expand Opioid Use Disorder Treatment. Northwestern University's Institute for Public Health and Medicine and the Buehler Center for Health Policy and Economics. February 22, 2024.

DORM: Data-Informed Overdose Risk Mitigation. National Governors Association Panel Meeting. March 24, 2023.

Sailing into Favorable Winds? Policy Opportunities to Improve Opioid Use Disorder Treatment in Correctional Facilities. National Corrections Association Meeting. February 23, 2023.

Impact of Administering Buprenorphine to Overdose Survivors Using Emergency Medical Services. Maryland Emergency Medical Services Advisory Group. January 2023.

Was Buprenorphine Treatment for OUD the Dog that Didn't Bark in the Pandemic? IQVIA Research Forum. October 10, 2022.

OUD Treatment without Red Tape: What We Learned During the COVID-19 Pandemic. American Society of Addiction Medicine. State of the Art Course. September 29, 2022.

Not Equivalent, But Better: Human Rights and Health Care Behind Bars in the Time of COVID. Bioethics Grand Rounds. University of Minnesota. September 23, 2022.

Use of Buprenorphine During Incarceration and Post-Release Outcomes. Delaware Department of Health and Human Services. July 14, 2022.

Regulating Methadone in Correctional Facilities and Our National Data Challenge. NASEM methadone workshop. March 4, 2022.

(with Noa Krawczyk) Current Trends in the Treatment of Opioid Use Disorder with Buprenorphine. American Osteopathic Academy of Addiction Medicine. March 24, 2021. Virtual Presentation.

Medications for Opioid Addiction Behind Bars: Insights from the Delaware Department of Correction. ACCEL Innovative Discoveries Series. March 19, 2021. Virtual Presentation.

Access to Care and Treatment Utilization for MHSUD during COVID-19: Early Evidence. National Academies Forum. December 3, 2020. Virtual Presentation.

Public Health Principles for the Opioid Settlement Funds. Bloomberg Opioids Meeting. December 4, 2019. New York, NY.

Evidence-Based Public Health Strategies for the Opioid Crisis. NPSC Congressional Briefing. November 19, 2019. Washington, DC.

Finding the Most At Risk: A Predictive Risk Model for Opioid Overdose in Maryland. Johns Hopkins Bayview Medical Campus. Behavioral Pharmacology Research Unit. October 9, 2019. Baltimore, MD.

Linking Criminal Justice and Medical Data to Predict Opioid Overdose: Evidence from Maryland. Yale Health Policy and Management Seminar. September 18, 2019. New Haven, CT.

Finding the Most At Risk: Linking Health and Criminal Justice Data to Predict Opioid Overdose. University of Pittsburgh Public Health Seminar Series. March 26, 2019. Pittsburgh, PA.

The Opioid Crisis in Maryland. Johns Hopkins Health Advisory Board. October 12, 2018. Baltimore, MD.

A Blueprint for Transforming Opioid Use Disorder Treatment in Delaware: Summary of Recommendations and Next Steps. Lieutenant Governor's Behavioral Health Consortium. July 24, 2018. New Castle, Delaware.

If you pay for it will they come? Substance Use Disorder Treatment under the ACA Medicaid Expansion. RAND Applied Economics Seminar. March 26, 2018. Santa Monica, CA.

Linking Criminal Justice and Health Data to Predict Opioid Overdose. The Lab@DC Forum. February 27, 2018. Washington, DC.

The Affordable Care Act in the Heart of the Opioid Epidemic: Evidence from West Virginia. Michael M. Davis Lecture. University of Chicago Center for Health Administration Science. November 7, 2017. Chicago, IL.

Using Data Science to Identify Individuals at High Risk of Opioid Overdose. Centers for Medicare and Medicaid Services Innovation Center. August 8, 2017.

The Impact of the Affordable Care Act on Access to Treatment for Substance Use Disorders. Invited seminar. Urban Institute Health Policy Center. April 25, 2017. Washington, DC.

Substance Use Disorder Treatment Among Criminal Justice-Involved Adults: Trends from 2004 to 2014. Health Affairs Briefing on Behavioral Health. June 7, 2016. Washington, DC.

The Impact of a State Autism Coverage Mandate: Evidence from Kansas. Emory University Applied Microeconomics Seminar. March 24, 2016. Atlanta, GA.
Changes in Service Use After a State Autism Coverage Mandate: Evidence from Kansas. Virginia Commonwealth University Health Services Seminar. November 5, 2015. Richmond, VA.

Changes in Service Use After a State Autism Coverage Mandate: Evidence from Kansas. University of Maryland HSA seminar. October 22, 2015. College Park, MD.

You Can't Eat Health Care: Philosophical Challenges to Incorporating Health Spending Needs into a Poverty Measure. SPA Faculty Seminar, CUNY Baruch College. October 15, 2014. New York, NY.

ADDITIONAL INFORMATION

Personal statement

Brendan Saloner, PhD, is the Donald G. Millar Professor of Alcohol and Addiction Studies in the Department of Health Services, Policy, and Practice. One strand of his research focuses on access and quality of care for people with mental health and substance use disorders. He has received funding awards from the National Institute on Drug Abuse (NIDA) and Arnold Ventures to study opioid use disorder treatment, including recent grants to study the implementation of mobile methadone treatment in New York state and urine drug testing for patients with opioid use disorder. At Johns Hopkins, he co-led the evaluation team for the Bloomberg Overdose Prevention Initiative, a \$120 million investment in overdose reduction focused on seven states. A second strand of his research focuses specifically on health care for people in the criminal legal system. He has also received grants from NIDA and Arnold Ventures to investigate medications for opioid use disorder among incarcerated people. He is currently evaluating the statewide expansion of addiction treatment in Maryland county detention facilities. Finally, Professor Saloner maintains an active research program in bioethics. He led a Making a Difference grant supported by the Greenwall Foundation to study resource allocation in jails and prisons during the COVID-19 pandemic. He received the Greenwall Faculty Scholars Award in 2023 for a project focused on ethical issues related to mandated addiction treatment for people in the criminal legal system. Professor Saloner has an extensive interest in policy engagement. He has testified in the U.S. Senate, consulted with federal and state agencies, and has engaged in technical assistance projects.

Keywords

Medicaid, substance use disorders, opioid use disorder, incarceration, child and adolescent health, access to care, justice and resource allocation, primary care, health services research, social policy, health policy.